DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  1  
  
 
 
 
A Phase  1, Open -Label,  Dose -Escalation  Trial  to Evaluate  the 
Safety, Reactogenicity, and Immunogenicity of the Sm -p80 + 
GLA -SE (SchistoShield®) Vaccine in Healthy Adults  
 
 
DMID  Protocol  Number:  18-0018  
 
DMID  Funding  Mechanism:  Infectious  Disease  Clinical  Research  Consortium  
 
Pharmaceutical  Support:  PAI Life Sciences  Inc.; Infectious  Disease  Research  Institute  
 
IND Sponsor:  Division  of Microbiology  and Infectious  Diseases,  National  Institute  of Allergy 
and Infectious Diseases, National Institutes of Health  
 
Lead Principal Investigator: [INVESTIGATOR_122731] A. Jackson, MD, MPH 
DMID  Clinical  Project  Manager:  Ranjodh  Gill, BSN,  MPH 
Version:  4.0 
04 January  2024  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  2  
  
 
 
 
STATEMENT  OF ASSURANCE  
 
Each Institution will hold a current Federal Wide Assurance (FWA) issued by [CONTACT_122780] (OHRP)  for federally -funded  human  subjects research.  Each FWA 
will designate at least one Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) registered with OHRP, for which the research will be reviewed and approved by [CONTACT_5040]/IEC and will be subject to continuing review [45 CFR 46.103(b)]. The IRB/IEC designated 
under  an FWA  may include  an institution’s  IRB/IEC,  an independent  IRB/IEC,  or an IRB/IEC  of 
another institution after establishing a written agreement with that other institution.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  3  
  
 
 
 
STATEMENT  OF COMPLIANCE  
 
The study  trial will be carried  out in accordance  with the protocol,  Good  Clinical  Practice  (GCP) 
and as required by [CONTACT_716]:  
• United  States  Code  of Federal  Regulations  (CFR)  45 CFR  Part 46: Protection  of Human 
Subjects  
• Food  and Drug  Administration  (FDA)  Regulations,  as applicable: 21  CFR  Part 50 (Protection 
of Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230]), 21  
CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21 CFR Part 312 
(Investigational New Drug Application), 21 CFR 812 (Investigational Device Ex emptions)  
• International  Conference  on Harmonisation:  Good  Clinical  Practice  (ICH  E6); 62 Federal 
Register [ZIP_CODE] (1997); and future revisions  
• Belmont  Report:  Ethical  Principles  and Guidelines  for the Protection  of Human  Subjects  of 
Research, Report of the N ational Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research  
• National  Institutes  of Health  (NIH)  Office  of Extramural  Research,  Research  Involving 
Human Subjects, as applicable  
• National  Institute  of Allergy  and Infectious  Diseases  (NIAID)  Clinical  Terms  of Award,  as 
applicable  
• Applicable  Federal,  State,  and Local  Regulations  and Guidance  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  4  
 Site Inve stigator  Signature:   
 
[INVESTIGATOR_14586]:    
Date:  
Lisa A. Jackson,  MD, MPH  
Senior  Investigator,  Kaiser  Permanente  Washington 
Health Research Institute  
  
 
 
 
SIGNATURE  [CONTACT_122866], including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable [LOCATION_002] (US)  federal 
regulations and ICH E6 GCP guidelines.  
I agree  to conduct  the study  in compliance  with GCP  and applicable  regulatory  requirements.  
I agree  to conduct  the study  in accordance  with the current  protocol  and will not make  changes  to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except when 
necessary to protect the safety, rights, or welfare of subjects.  
 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138077]  OF ABBREVIATI ONS  ................................ ................................ ................................ ........  12 
PROTOCOL  SUMMARY  ................................ ................................ ................................ .............  15 
KEY  ROLES  ................................ ................................ ................................ .........................  19 
BACKGROUND  AND  SCIENTIFIC  RATIONALE  ................................ ...........................  20 
Background  ................................ ................................ ................................ .................  20 
2.1.1 Schisto somiasis ................................ ................................ ...............................  20 
2.1.2 SchistoShield®  ................................ ................................ ...............................  22 
2.1.3 Preclinical  and Safety  Studies  ................................ ................................ ........  23 
[IP_ADDRESS]  Potency  of Sm-p80 in Murine  Models  ................................ ..............  23 
[IP_ADDRESS]  Safety and Immunogenicity of Sm -p80 + GLA -SE in Non -Human  
Primates  ................................ ................................ .............................  25 
[IP_ADDRESS]  Efficacy  of Sm-p80 + GLA -SE in Non-Human  Primates  .................  27 
2.1.4 Safety  of GLA -SE ................................ ................................ ..........................  28 
2.1.5 GLP  Toxicity  Studies  of SchistoShield®  ................................ .......................  [ADDRESS_138078] IVES  AND  ENDPOINTS  OR OUTCOME  MEASURES  ....... 35 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  6  
 Study  Design  Description  ................................ ................................ ............................  35 
Study  Objectives  ................................ ................................ ................................ .........  36 
3.2.1 Primary  ................................ ................................ ................................ ...........  36 
3.2.2 Secondary  ................................ ................................ ................................ ....... 36 
3.2.3 Exploratory  ................................ ................................ ................................ ..... 36 
Study  Endpoints  or Outcome  Measures  ................................ ................................ ...... 36 
3.3.1 Primary  ................................ ................................ ................................ ...........  36 
3.3.2 Secondary  ................................ ................................ ................................ ....... 36 
3.3.3 Exploratory  ................................ ................................ ................................ ..... 37 
STUDY  INTERVENTION/INVESTIGATIONAL  PRODUCT  ................................ ...........  [ADDRESS_138079]  Storage  and Stability  ................................ ................................ .........  39 
Acquisition/Distribution  ................................ ................................ ..............................  40 
Dosage/Regimen, Preparation, Dispensing and Administration of Study  
Intervention/Investigational  Product  ................................ ................................ .........  40 
Accountability  Procedures  for the Study  Intervention/Investigational  Product(s)  ...... 41 
Modification  of Study  Intervention/Investigational  Product  for a Participant  ............  [ADDRESS_138080]  Replacement  ................................ ................................ ......................  49 
5.2.3 Study  Termination  ................................ ................................ ..........................  49 
STUDY  PROCEDURES  ................................ ................................ ................................ ....... 51 
Screening,  Visit  00 (Day -30 to Day -1) ................................ ................................ ..... [ADDRESS_138081]  Injection,  Clinic  Visit  .............  53 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  7  
 Planned  Study  Visits  ................................ ................................ ................................ ... 54 
6.3.1 Follow -up ................................ ................................ ................................ ....... 55 
6.3.2 Early  Termination  Visit  ................................ ................................ ..................  56 
Unscheduled  Study  Visits  (if needed)  ................................ ................................ .........  57 
Protocol  Deviations  ................................ ................................ ................................ ..... 57 
DESCRIPTION  OF CLINICAL  AND  LABORATORY  EVALUATIONS  .........................  58 
Clinical  Evaluations  ................................ ................................ ................................ .... 58 
7.1.1 Assessment of Concomitant Medications/Treatments other than Study  
Product  ................................ ................................ ................................ ...........  59 
Laboratory  Evaluations  ................................ ................................ ...............................  60 
7.2.1 Clinical  Laboratory  Evaluations  ................................ ................................ ..... 60 
7.2.2 Research  Assays  ................................ ................................ .............................  60 
[IP_ADDRESS]  ELISA  (anti Sm-p80 IgG) ................................ ................................ . 61 
[IP_ADDRESS]  RNA -Seq ................................ ................................ ...........................  61 
[IP_ADDRESS]  Laboratory  Specimen  Preparation,  Handling,  and Storage  ...............  61 
[IP_ADDRESS]  Laboratory  Specimen  Shippi[INVESTIGATOR_007]  ................................ .........................  61 
ASSESSMENT  OF SAFETY  ................................ ................................ ...............................  63 
Assessing  and Recording  Safety  Parameters  ................................ ..............................  63 
8.1.1 Adverse  Events  (AEs)  ................................ ................................ ....................  63 
[IP_ADDRESS]  Adverse  Events  Grading  ................................ ................................ ... 64 
8.1.2 Reactogenicit y ................................ ................................ ................................  66 
8.1.3 Serious  Adverse  Events  (SAEs)  ................................ ................................ ..... 68 
Specification  of Safety  Parameters  ................................ ................................ .............  69 
8.2.1 Solicited  Events  ................................ ................................ ..............................  69 
8.2.2 Unsolicited  Events  ................................ ................................ ..........................  69 
8.2.3 New -Onset  Chronic  Medical Conditions  (NOCMCs) ................................ .... 69 
8.2.4 Medically -Attended  Adverse  Events  (MAAEs)  ................................ .............  69 
8.2.5 Potentially  Immune -Mediated  Medical  Conditions  (PI[INVESTIGATOR_106279])  .....................  69 
Reporting  Procedures  ................................ ................................ ................................ .. 69 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138082]/Independent  Ethics  Committee  ................................ ........  76 
Informed  Consent  Process  ................................ ................................ ...........................  76 
9.2.1 Requirements for Permission by [CONTACT_122781]/Guardians and Assent by [CONTACT_63779]  
(in case of a minor)  ................................ ................................ .........................  78 
9.2.2 Other  Informed  Consent Procedures  ................................ ..............................  78 
Consent  for Secondary  Research  Use of Stored  Specimens  and Data ........................  78 
9.3.1 Secondary  Use of Stored  Specimens  and Data ................................ ...............  78 
9.3.2 Samples  for Secondary  Research  ................................ ................................ ... 79 
9.3.3 Data  Sharing  for Secondary  Research  ................................ ............................  80 
Exclusion  of Women,  Minorities,  and Children  (Special  Populations)  ......................  [ADDRESS_138083]  Compensation,  and Research  Related  Injuries  ................................ .... 81 
STATISTICAL  CONSIDERATIONS  ................................ ................................ ..................  83 
Study  Hypotheses  ................................ ................................ ................................ ........  83 
Sample  Size Considerations  ................................ ................................ ........................  83 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  9  
 Treat ment  Assignment  Procedures  ................................ ................................ ..............  83 
10.3.1  Randomization  Procedures  ................................ ................................ .............  83 
10.3.2  Masking  Procedures  ................................ ................................ .......................  84 
Planned  Interim  Analyses  ................................ ................................ ...........................  84 
10.4.1  Interim  Safety  Review  ................................ ................................ ....................  84 
10.4.2  Interim  Immunogenicity  or Efficacy  Review  ................................ .................  85 
Final  Analysis  Plan ................................ ................................ ................................ ..... 85 
10.5.1  Analysis  of Demographics ................................ ................................ ..............  85 
10.5.2  Analysis  of Safety  Data ................................ ................................ ..................  85 
10.5.3  Analysis  of Immunogenicity  Data ................................ ................................ .. 86 
10.5.4  RNA -Seq Analysis  ................................ ................................ .........................  86 
SOURCE  DOCUMENTS  AND  ACCESS  TO SOURCE  DATA/DOCUMENTS  ...............  [ADDRESS_138084]  KEEPI[INVESTIGATOR_1645]  ................................ ................................ . 90 
Data  Management  Responsibilities  ................................ ................................ .............  90 
Data  Coordinating  Center/Biostatistician  Responsibilities  ................................ .........  [ADDRESS_138085] of Potentially  Immune -Mediated  Medical  Conditions  (PI[INVESTIGATOR_106279])  
105 
Toxicity  Tables  ................................ ................................ ...............  108 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138086]  OF TABLES  
 
Table  1: Treatment  Arms  ................................ ................................ ................................ ...............  17 
Table  2: Dose  Escalation  Schedule.  ................................ ................................ ...............................  18 
Table  3: Injection  Site Reactogenicity  Grading  ................................ ................................ .............  66 
Table  4: Injection  Site Reactogenicity  Measurements  ................................ ................................ ... 66 
Table  5: Subjective  Systemic  Reactogenicity  Grading  ................................ ................................ .. 67 
Table  6: Quantitative  Systemic  Reactogenicity  Grading  ................................ ...............................  67 
Table  7: Screening  Visit  Evaluations  and Procedures.  ................................ ................................ ... 98 
Table  8: Schedule  of Events  and Study  Procedures,  Study  Groups  A, B, D, and E .......................  99 
Table  9: Schedule  of Events  and Study  Procedures,  Study  Group  C ................................ ...........  102 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138087]  OF FIGURES  
Figure  1: Infographic  on the potential  impact  of the SchistoShield®  vaccine.  ..............................  20 
Figure  2: Sm-p80-specific  Total  IgG Titers  in Mice  ................................ ................................ ...... 24 
Figure  3: Sm-p80 + GLA -SE Vaccine -Mediated  Efficacy  in Mice  ................................ ...............  25 
Figure  4: Kinetics  of total Sm-p80-specific  antibody  in immunized  baboons.  ..............................  26 
Figure  5: Prophylactic efficacy  of the Sm-p80 vaccine in baboons.  ................................ ..............  28 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138088]  OF ABBREVIATIONS  
 
 
ADCC  Antibody -dependent  cellular  cytotoxicity  
AE Adverse  event  
ALT  Alanine  aminotransferase  
ASC  Antibody  secreting  cell 
BMI Body  mass  index  
CFR Code  of Federal  Regulations  
CI Confidence  interval  
CMS  Clinical  Material  Services  
CRP C reactive  protein  
DMID  Division  of Microbiology  and Infectious  Diseases,  NIAID, 
NIH 
eCRF  Electronic  Case  Report  Form  
ELISA  Enzyme -linked  immunosorbent  assay  
FDA  Food  and Drug  Administration  
FWA  Federal  Wide  Assurance  
GCP  Good  Clinical  Practice  
GLA -SE Glucopyranosyl  Lipid Adjuvant  Stable  oil-in-water  Emulsion  
HBsAg  Hepatitis  B surface  antigen  
HCV  Hepatitis  C virus  
HEENT  Head,  ears, eyes,  nose,  and throat  
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonisation  
ICS Intracellular  cytokine  staining  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138089]  Monophosphoryl  Lipid  A 
N Number  (typi[INVESTIGATOR_122732])  
NIAID  National  Institute  of Allergy  and Infectious  Diseases,  NIH 
NIH National  Institutes  of Health  
NOCMC  New  onset  chronic  medical  condition  
OHRP  Office  for Human  Research  Protections  
PBMC  Peripheral  blood  mononuclear  cell 
PHA  Phytohemagglutinin  
PHI Protected  health  information  
PI [INVESTIGATOR_122733]/Serious  Adverse  Experience  
SCRI  Seattle  Children’s  Research Institute  
SDCC  Statistical  Data  Coordinating  Center  
SE Stable  emulsion  
SMC  Safety  Monitoring  Committee  
Sm-p80 S. mansoni  calpain  protein  with a mass  of approximately  80 
kDa 
TTUHSC  [LOCATION_007]  Tech  University  Health  Sciences  Center  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  14  
  
 
US United  States  
VTEU  Vaccine  and Treatment  Evaluation  Unit 
WBC  White  blood cell 
WFI Water  for Injection  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  15  
  
 
 
 
PROTOCOL  SUMMARY  
 
 
 
 
 
Title:  A Phase  1, Open -Label,  Dose -Escalation  Trial  to Evaluate  the 
Safety, Reactogenicity, and Immunogenicity of the Sm -p80 + 
GLA -SE (SchistoShield®) Vaccine in Healthy Adults  
Design  of the Study:  The study is a Phase 1 dose -escalation clinical trial to evaluate 
the safety,  reactogenicity,  and immunogenicity  of the Sm-p80 + 
GLA -SE vaccine candidate in healthy adults. Five treatment 
groups, each including nine subjects, will receive three 
intramuscul ar (IM)  injections  of 0.[ADDRESS_138090] on either Days 1, 29, and 57 or on Days 1, 29, and 180 
(Table  1). Group  A (unadjuvanted  comparator)  will receive  100 
μg Sm -p80 alone on Days 1, 29, and 57, Group B (low dose 
standard schedule) will receive 10 μg Sm -p80 + 5 μg GLA -SE 
on Days 1, 29 and 57, Group C (mid dose delayed booster) will 
receive 30 μg Sm -p80 + 5 μg GLA -SE on Days 1, 29 and 180, 
Group D (mid dos e standard schedule) will receive 30 μg Sm - 
p80 + 5 μg GLA -SE on Days 1, 29, and 57, and Group E (high 
dose standard schedule) will receive 100 μg Sm -p80 + 5 μg 
GLA -SE on Days 1, 29 and 57.  
Study  Phase:  1 
Study  Population:  45 healthy  adults 18  through 55 years  of age in the [LOCATION_002].  
Number  of Sites:  [ADDRESS_138091]:  Sm-p80 + GLA -SE, SchistoShield®, consists of Sm -p80, a 
recombinant protein produced in Escherichia coli , and 
Glucopyranosyl Lipid Adjuvant (GLA) formulated in a stable 
emulsion  (GLA -SE) as an immunological  adjuvant.  The Sm-p80 
+ GLA -SE vaccine has not yet been studied in humans. The 
study  will evaluate  an antigen  only formulation  with 100 μg Sm- 
p80 and three  adjuvanted formulations  with varying  antigen  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  16  
  
 
 content (10 μg, 30 μg, or 100 μg Sm -p80, all with 5 μg GLA - 
SE). An injected  volume  of 0.5 mL will be administered  for all 
three doses. All formulations will be evaluated on a Day 1, 29 
and 57 administration schedule; the 30 μg + [ADDRESS_138092] schedule.  
Study  Objectives:  Primary:  
• To assess  the safety  and reactogenicity  following  receipt  of 
three doses of 1) 100 µg Sm -p80 (unadjuvanted), 2) 10 µg  
Sm-p80 + 5 µg GLA -SE, 3) 30 µg Sm-p80 + 5 µg GLA -SE, 
and 4) 100 µg Sm -p80 + 5 µg GLA -SE administered 
intramuscularly  on Days  1, 29, and 57 and 5) 30 µg Sm-p80 
+ 5 µg GLA -SE administered  on Days  1, 29, and 180. 
Secondary:  
• To assess  anti- Sm-p80 IgG antibody  responses  from  samples 
collected at specified time points.  
 
Exploratory:  
• To assess  innate  and adaptive  immune  signatures  from 
samples collected at specified time points.  
Duration  of Individual 
Subject Participation:  Approximately 15 months (screening visit through last study 
visit) for subjects with the Day 1, [ADDRESS_138093]/Last  Study  Day:  Approximately  twenty  months:  four weeks  initial  screening,  six 
weeks to progress to enrollment of the delayed booster dose 
cohort (Group C) ( Table 2 ), and study follow -up through day 
[ADDRESS_138094].  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  17  
  
 
 
 
Table  1: Treatment  Arms.  
 
Study  
Group  N Study  Product  Administration  Schedule  
A 9 100 µg Sm-p80 (unadjuvanted)  Day 1, 29, 57 
B 9 10 µg Sm-p80 + 5 µg GLA -SE Day 1, 29, 57 
C 9 30 µg Sm-p80 + 5 µg GLA -SE Day 1, 29, 180 (delayed  booster)  
D 9 30 µg Sm-p80 + 5 µg GLA -SE Day 1, 29, 57 
E 9 100 µg Sm-p80 + [ADDRESS_138095] ( Table 1 ). The safety profile of either  
formulation does not necessarily predict that of the other. Therefore, Groups A and B will be 
enrolled before  the first safety data review ( Table 2 ). For each of those  Groups, only one subject 
will receive vaccine on the first day of administration of that formulation.  
To progress to the next dose level, the Principal Investigator (PI) will review safety data  
collec ted through at least seven days after the first injection of the Group A and Group B  
subjects and assess this data according to pre -specified criteria for halting dose escalation 
(Section 8.6.3 ). If dose escalation halting criteria are not met, Study Groups C and D subjects, 
who will receive the next highest dose of 30 µg Sm -p80 + [ADDRESS_138096] will be vaccinated. For both dose escalation 
safety reviews, to allow progression to Groups C and D and then to Group E, if dose escalation 
halting  criter ia are met, all vaccine  administrations  will pause.  The Safety  Monitoring  Committee 
(SMC)  will then review  the safety  data and must  approve  dose escalation  before vaccinations  can 
resume.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  18  
  
 
 
 
Table  2: Dose  Escalation  Schedule.  
 
Week  Group  A Group  B Group  C Group  D Group  E 
Number  of subjects  receiving  first study  product  injections  by [CONTACT_5875]  
[ADDRESS_138097]  injection for  Groups  C and D 
9      
10     9 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  19  
  
 
 
 
KEY  ROLES  
 
 
 
 
 
Lead  Principal 
Investigator:  [INVESTIGATOR_122731] A. Jackson,  MD, MPH  
Kaiser  Permanente  Washington  Health  Research  Institute  
 
 
DMID  Clinical  Project 
Manager:   
 
Ranjodh  Gill, MPH  
Parasitology  and International  Programs  Branch,  DMID, 
NIAID  
 
Statistical and Data 
Coordinating  Center:   
The Emmes  Company, LLC 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138098] burden in sub -Saharan Africa ( Figure 1 ). Eight hundred million people 
are at risk in 78 countries, and 240 million are already infected. Seroprevalence studies a re 
scarce, but available data indicate that up to 90% of persons living in high -risk areas acquire a 
schistosome infection at some point, usually before 10 years of age, resulting in a high 
prevalence  in school -aged children. Of  deaths caused by [CONTACT_122782],  schistosomiasis ranks second 
only to Plasmodium falciparum malaria, killing 280,000 people annually in sub -Saharan Africa 
alone.  
Figure  1: Infographic  on the potential  impact  of the SchistoShield®  vaccine.  
 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  21  
  
 
 
Schistosomiasis is caused by a trematode worm of the Schistosoma genus, a parasitic blood 
fluke.[1] During the infectious stages, they are released from snails in fresh water. Prolonged 
infection can result in complex or gan manifestations. Intestinal schistosomiasis is caused by S. 
mansoni and occurs in sub -Saharan Africa, the Mediterranean, the Caribbean, and South 
America. S. intercalatum causes intestinal schistosomiasis and occurs in Central Africa. Oriental 
or Asiati c schistosomiasis is caused by [CONTACT_941] S. japonicum group of parasites (including S. 
mekongi ) and is endemic to Southeast Asia. Finally, S. haematobium causes urinary 
schistosomiasis and is endemic to Africa and the Mediterranean. The life cycle of schistosome s 
starts with the release of cercariae by [CONTACT_122783]. Human infection occurs when cercariae 
actively  penetrate  the skin and enter  the body.  The larvae  invade  host blood vessels,  develop  into 
adult schistosomes and multiply. Female schistosomes relea se eggs into the bloodstream. Eggs 
may be excreted through urine or feces and contaminate water sources, completing the 
schistosome  life cycle.  Eggs  that are not excreted  can become  lodged  in human  tissue  and trigger 
immune reactions that result in clinica l disease.  
Clinical  misclassification  of schistosomiasis  is common.  The current  diagnostic  gold standard  is 
microscopic examination of stool or urine for eggs but is not sensitive enough to identify mild 
infections (i.e., adult worms may not have produced detectable eggs) and 20 -30% of infections 
may be missed due to intermittent excretion of eggs in stool or  urine  resulting in a systematic 
underestimation of the burden.[2,3] Adjusting for diagnostic sensitivity, the global burden of 
schistosomiasis estimated in 2007 was 391 -587 million cases.[4] The mainstay of 
schistosomiasis control is preventative and ther apeutic administration of the anthelminthic 
praziquantel. However, repeated treatment is needed for curative parasite clearance. A single 
infection does not prevent future infection; as such, the cost -effectiveness of mass -treatment 
programs is compromised  when reinfection is common.  
To combat the schistosomiasis burden, large -scale prevention strategies (e.g., mass vaccination 
campaigns)  that complement  treatment  programs  are necessary.  According  to the World  Health 
Organization,  target  groups  for large -scale,  periodic  treatment  include  school -aged  children  and 
high-risk adults (e.g., fishermen, farmers, irrigation workers, and other persons who have 
increased contact [CONTACT_122784]) or entire communities living in highly endemic areas.  
Periodi c praziquantel treatment has been shown to reduce clinical symptoms; however, there 
remains  a gap between  those  who require  and those  who receive  treatment.  According  to a 2015 
estimate, only 28% of overall cases requiring treatment received care. An alternative or 
supplementary control method is the reduction of intermediate snail hosts using molluscicides, 
but this is even more challenging and costly  since frequent applica tion of molluscicides is 
necessary and logistically challenging.[5]  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138099].[6,7] A combined control approach that 
couples mass treatment with vaccination will significantly reduce worm loads and break the 
transmission cycle, allowing for the eventual elim ination of schistosomiasis.[8 -10] 
2.1.2 SchistoShield®  
The proposed vaccine candidate, SchistoShield® (Sm -p80 [antigen] + GLA -SE [adjuvant 
formulation]), targets the Sm -p80 surface membrane antigen, which is the heavy chain of the S. 
mansoni  calcium  activated  neutral protease  (calpain),  and includes  a Toll-like receptor  [ADDRESS_138100] - 
based adjuvant formulation (GLA -SE). Sm-p80 stands for S. mansoni calpain protein with a 
mass of approximately 80 kDa and GLA stands for Glucopyranosyl Lipid Adjuvant -Stable oil - 
in-water Emulsion. The vaccine antigen is an E. coli – produced recombinant Sm -p80 calpain 
protein from S. mansoni , manufactured, filled, and released by [CONTACT_122785]. (Seattle, 
WA). The vaccine adjuvant formulation, GLA -SE, is a synthe tic Lipid A – like molecule and 
Toll-like receptor [ADDRESS_138101] formulated in a  squalene  emulsion manufactured and released by [CONTACT_122786] (IDRI) (Seattle, WA).  
 
Development  of effective  recombinant  protein  vaccines  for S. manson i is possible  for the 
following reasons:  
• Unlike  protozoan  parasites,  helminths  such as Schistosoma  do not undergo  significant 
antigenic variation.  
• Schistosoma  live as two sexes  in the circulation,  where  they are exposed  to antibodies  and 
their effector functions.  
• While both sexes express Sm -p80 on their surface, the female worms – which cause 
pathology  due to egg deposition  – have  a higher  density  of Sm-p80 on their surface,  making 
them most vulnerable to the action of the vaccine.  
• While some regions of the targeted deployment countries have both S. mansoni , from which 
Sm-p80 is derived, and S. haematobium, the causative agent of urinary schistosomiasis, our 
data suggest  that cross -species  efficacy  is induced  by [CONTACT_29500],  likely  due to the high level 
of homology between the proteins.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  23  
  
 
 
• Safe and effective adjuvants that preferentially induce T H1 responses are now available; the 
proposed  GLA -SE adjuvant  has been  extensively  tested  with Sm-p80, as well as in thousands 
of human subjects.  
2.1.3 Preclinical  and Safety  Studies  
Sm-p80 has been  tested  for its vaccine  efficacy  in different  vaccine  formulations  and approaches. 
These include naked DNA, recombinant protein, and DNA prime/protein boost in three 
experimental animal models of infection and disease (mouse, hamster, and baboon). These Sm - 
p80-based vaccines provided comprehensive coverage against differ ent stages of the parasite’s 
life cycle, including its eggs, schistosomula, and adult worms. Sm -p80 is unique in that it has 
demonstrated desirable outcomes of Sm -p80 vaccination including: 1) prophylactic efficacy 
against S. mansoni (intestinal/hepatic sc histosomiasis);[9]; 2) reduction in egg -induced 
tissue/organ pathology;[9] 3) post -exposure therapeutic efficacy by [CONTACT_122787];[11] 4) cross species -protection against S. haematobium (urinary 
schistosomiasis)[ 12] and S. japonicum (Asiatic/oriental disease);[13] 5) long lived immunity as 
Sm-p80 specific IgG titers are present in mice for up to 60 weeks and 5 -8 years in baboons;[14] 
and 6) maternal transfer of Sm -p80-specific antibodies in baboons.[14] Sm -p80-specific IgE has 
not been detected in high -risk or infected populations from Africa and South America, thus 
reducing the possibility of hypersensitivity following vaccination with the Sm -p80 vaccine in 
humans. The protective immune response to Schistosoma is thought to be antibody mediated  
with cell -mediated help to skew the antibody isotypes to IgG1 and IgG3.  
This section  includes  descriptions  of preclinical  and safety/immunogenicity  experiments  with the 
Sm-p80 recombinant protein antigen. Summaries of the fo llowing studies are included:  
• Representative  preclinical  studies  in murine  models  of schistosomiasis  that demonstrate 
protective immunity induced by [CONTACT_33853];  
• Safety,  immunogenicity,  and efficacy  studies  of the SchistoShield®  vaccine  in a nonhuman 
primate model. The Sm -p80-based vaccine was evaluated in 40 baboons ( Papio anubis ), 
natural hosts of schistosomiasis and the most relevant nonhuman primate model of human 
clinical manifestations of both acute and chronic disease.  
[IP_ADDRESS]  Potency  of Sm-p80 in Murine  Models  
The rSm -p80 antigen was tested for its prophylactic and anti -pathology efficacy in murine 
challenge models. Briefly, groups of mice were immunized three times, four weeks apart. At 
week twelve, four weeks after the last boost, mice were c hallenged with 150 cercariae of S. 
mansoni via tail immersion. Serum samples were collected via tail bleed before every 
immunization  and before  challenge.  The mice  were  sacrificed  six to eight weeks  after challenge.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  24  
  
 
 
Protection (P) was calculated by [CONTACT_122788] (V) and control (C) 
animals  by a standard  formula:  %P = [(CV)/C  x 100)].  After  sacrifice,  liver and intestine  samples 
were collected from each animal and digested in 4% KOH. The number of eggs present in the 
tissues and percent reduction in egg production was determined. Antibody responses to Sm -p80 
in immunized mice were estimated by [CONTACT_122789] -linked immunosorbent assay (E LISA). In sera 
collected from these mice distinct Sm -p80-specific antibody titers were obtained for total IgG.  
Animals immunized with adjuvant alone did not exhibit any significant IgG titers. However, 
robust antigen -specific (Sm -p80) IgG titers were detec ted in the vaccine group. These titers 
reached  end-point  titers  of 1:1,638,400  at weeks  10 and 12 (Figure  2). These  results  demonstrate 
that the Sm -p80 antigen produced is highly antigenic whe n given with GLA -SE. 
The SchistoShield® vaccine was able to significantly reduce the number of worms found in 
experimental animals. The levels of protection (62.69%) recorded are high for a murine model. 
The SchistoShield®  vaccine  was also able to significantly  reduce  eggs in both liver and  intestine. 
Eggs in the liver and intestine were reduced by 92.57% and 87.46%, respectively, compared to 
control animals. Also significant, the vaccine was again able to preferentially kill female worms. 
Specifically, 89% of female worms were  killed in the vaccine group ( Figure 3 ). 
Figure  2: Sm-p80-specific  Total  IgG Titers  in Mice  
 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  25  
  
 
 
 
Figure  3: Sm-p80 + GLA -SE Vaccine -Mediated  Efficacy  in Mice.  
 
[IP_ADDRESS]  Safety  and Immunogenicity  of Sm-p80 + GLA -SE in Non-Human  Primates  
There were four independent double -blinded trials, with two groups of baboons (control an d 
experimental) in each trial. A total of 10 baboons were randomly and equally divided into either 
control  (n=5)  or experimental  (n=5)  groups  for each trial. Each  baboon  in the experimental  group 
received [ADDRESS_138102] immunization, each baboon was percutaneously challen ged with 1000 S. 
mansoni cercariae. To allow for disease  progression, all baboons remained under observation for 
8 weeks.  
In the baboon trials, no notable changes in blood chemistry were identified.  Blood chemistry 
evaluations  included  a complete  blood  count (including  white  blood  cell [WBC]  count,  red blood 
cell count, hemoglobin, hematocrit, and platelet count) and chemistries (including alkaline 
phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase, creatine kinase, 
gamma -glutamyl trans ferase, amylase, lipase, albumin, total protein, globulin, total and 
fractionated bilirubin, blood urea  nitrogen, creatinine, cholesterol, glucose, calcium, phosphorus, 
total carbon dioxide, chloride, potassium, sodium, albumin/globulin ratio, anion gap).  
There were also no notable vaccine -related clinical observations. Specifically, the baboons did 
not show any problems in eating, drinking, urinating, or defecating, they were alert and 
responsive  and no abnormal  animal  behaviors  were  noted.  No neurological /motor  problems  were 
observed and no signs of swelling, hyperemia, or induration at or around the injection site were 
identified.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138103]-prime  (Week  4), post-boosts  (Weeks  8, 12, 
and 16), and finally  post-challenge  (Week  24) by [CONTACT_6428]  (Figure  4). None  of the animals  had any 
antibody response against Sm -p80 at baseline (Week 0). In animals immunized with adjuvant 
alone no significant antibod y responses were detected. In contrast, groups immunized with 
SchistoShield® mounted antibody responses following the first vaccination (Week 4) and strong 
antibody titers were observed in all animals post -boosting and remained high after challenge.  
Figure  4: Kinetics  of total  Sm-p80-specific  antibody  in immunized  baboons.  
 
 
Panels  depi[INVESTIGATOR_122734]-p80-specific  total IgG antibodies  in control  animals  (C, GLA -SE) 
and experimental animals (E, rSm -p80 + GLA -SE) in Trials 1, 2, 3, and 4, respe ctively. Endpoint 
titers were determined for Weeks 0, 4, 8, 12, 16, and 24.  
 
 
The role of anti -Sm-p80 antibodies and complement activation in S. mansoni juvenile worm 
killing was examined in vitro . Data from the cytotoxicity assay showed that pooled sera f rom 
baboons  immunized  with Sm-p80/GLA -SE promoted  significant  in vitro  killing  of schistosomula 
(43.75%). Addition of active guinea pig complement to the Sm -p80 sera significantly increased 
the percentage of dead schistosomula to 87.72% (p < 0.001).  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  27  
  
 
 
[IP_ADDRESS]  Effica cy of Sm-p80 + GLA -SE in Non-Human  Primates  
The cumulative 40 -baboon study yielded a statistically significant reduction of 65.71% 
(p<0.0001) in total worm pairs in animals vaccinated with Sm -p80/GLA -SE (Figure 5 A); the 
protection was consistent across four independent experiments (Protection: Trial 1, 61.96%; 
Trial 2, 64.16%; Trial 3, 69.35%; Trial 4, 68.17%). Uniquely, the Sm -p80/GLA -SE vaccine can 
eliminate 93.45% (p<0.0001) of female paras ites, and this vaccine -mediated sex -preferential 
killing was similar amongst all the experiments (female worm killing: Trial 1, 93.27%; Trial 2, 
91.16%; Trial 3, 94.01%%; Trial 4, 95.19%). Less than 7% of the egg -producing females 
survived the vaccine effe ct, resulting in minimal pathology in host tissues/organs, as ascertained 
by [CONTACT_122790] (p<0.0001) reduction in egg retention in liver (91.35%), small intestine 
(85.69%), and large intestine (91.14%) in vaccinated animals ( Figure 5 B). Additionally, egg 
expulsion in feces was reduced by 40 -fold in vaccinated animals; 5 eggs per gram in feces was 
the average output in vaccinated animals, compared to 204 eggs per gram release in control 
animals ( Figure 5 C). Those eggs that were excreted were impaired in their ability to hatch into 
miracidia,  the parasite  stage  that infects  snails  to continue  the life cycle  with a 79.21%  inhibition 
of hatching for eggs obtained from vaccinated animals ( Figure 5 D). 
In summary,  the four trials  demonstrated  that the vaccine  is highly  efficacious  in the baboon 
model and leads to profound killing of pathogenic female worms.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  28  
  
 
 
 
Figure  5: Prophylactic  efficacy  of the Sm-p80 vaccine  in baboons.  
 
 
2.1.4 Safety  of GLA -SE 
The 5 µg dose of GLA -SE to be used in this trial is comfortably  in the mid-range  of tested  doses 
of the adjuvant  and has been  shown  to be safe and well tolerated  in hundreds  of human  subjects.  
Preclinical  Safety  
As reported in the GLA -SE Investigator Brochure (v5, March 2016) many preclinical and 
nonclinical studies in mice, guinea pi[INVESTIGATOR_14107], rats, rabbits, and non -human primates have  
demonstrated  the immunostimulatory  properties  of GLA -SE with no significant  safety  signals.  
Thousands  of mice  have  been  immunized  with candidate  antigens  for infectious  disease  vaccines 
(e.g., leishmaniasis, tuberculosis, leprosy, malaria, influenza) form ulated in GLA -SE. No safety 
issues have been observed when the following parameters were evaluated: clinical observations 
including  general  health  and mortality;  injection  site reactions;  body  weights;  food consumption; 
and, gross pathology. In addition, the potential for auto -antibody generation following GLA  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  29  
  
 
 
administration was evaluated through extensive immunohistochemistry assays for immune 
complexes and/or autoimmune pathology, and no signs of detrimental autoimmune effects were 
found.  Studies  have  also assayed  for anti-nuclear  antibody  and have  not found  abnormal  levels  in 
GLA -immunized mice.  
More than [ADDRESS_138104] been observed when the following 
paramete rs were  evaluated:  clinical  observations  including  general  health  and mortality;  injection 
site reactions; body weights; food consumption; and, gross pathology. In addition, a safety study 
was conducted in guinea pi[INVESTIGATOR_122735] (oil -in-water 
emulsions, aqueous suspensions, liposomes) were administered w ithout antigen by [CONTACT_122791] (subcutaneous, intramuscular  [IM], and intradermal). Administration of 
GLA -SE by [CONTACT_122792].  
GLA -SE has been tested in several safety, immunogenicity, and/or ef ficacy studies in nonhuman 
primates. The safety parameters evaluated included clinical observations, injection site 
evaluations, body weights, body temperatures, hematology, coagulation, clinical chemistry, and 
immunogenicity. In each study the adjuvant wa s safe, well tolerated, and increased the immune 
response to the co -administered antigen. No treatment -related adverse effects were observed in 
the safety  parameters  evaluated  except  for mild injection  site reactions  and a mild,  transient  acute 
phase infla mmatory response characterized by [CONTACT_122793] C -reactive protein (CRP), fibrinogen, 
and neutrophils.  
GLA -SE has been tested in several toxicity studies in rabbits and rats conducted under GLP 
guidelines. Parameters evaluated included the following: morbid ity/mortality; clinical signs; 
injection site reactogenicity; body weights; body temperatures; food consumption; 
ophthalmologic evaluations; clinical chemistry; hematology; coagulation; gross necropsy 
observations; organ weights; histopathology; and, immun ogenicity. In these studies, GLA -SE 
was found to be safe, well tolerated, and immunostimulatory. No treatment -related adverse 
effects were observed in the parameters evaluated except for reversible injection site reactions 
(erythema,  edema,  inflammation)  and a mild,  transient  acute  inflammatory  response  (changes  in 
hematologic values, increased fibrinogen levels) in some animals receiving GLA adjuvant 
formulations.  
Clinical  Experience  
GLA -SE has been  evaluated  in numerous  completed  or ongoing  clinical  trials.  These  trials  have 
investigated GLA -SE formulated with antigens, including recombinant antigens, developed for 
vaccines against a wide variety of diseases, including leishmaniasis,[15] tuberculosis,[16,17] 
influenza,[18,19] schistosomiasis,[20] and malaria[21]. These clinical trials have evaluated  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138105] revealed a generally 
acceptable safety profile:  
• Study  injections  are generally  well tolerated;  
• There  have  been  no serious  adverse  events (SAEs)  related  to study  injection;  
• Injection  site reactions  are common  and may include  pain,  tenderness,  erythema,  and 
induration;  
• Systemic  reactions  may include  headache,  fatigue,  anorexia,  fever,  chills,  myalgia, and 
arthralgia;  
• Transient  elevations  in CRP  levels  were  noted  in a study  of GLA -SE administered  with the 
Fluzone influenza vaccine; and  
• Hematologic  changes  may occur  (including  decreases  in hemoglobin,  WBC,  and 
neutrophils).  
These reactions varied from study to study, were generally mild, resolved quickly, and are 
typi[INVESTIGATOR_122736].  GLA -SE often  increases  the rate and severity  of local 
and systemic reactogenicity compared to the antigen alone. This is con sistent with the 
nonclinical animal experience and is to be expected of a potent immunostimulant.  
2.1.5 GLP  Toxicity  Studies  of SchistoShield®  
This GLP toxicology study was to evaluate the systemic toxicity and local tolerance of the 
SchistoShield® vaccine candi date protein antigen Sm -p80, both with and without GLA -SE, 
when administered by [CONTACT_122794]. Serum was also collected for 
immunogenicity  evaluations.  The study  was conducted  at Battelle  - West  Jefferson  in accordance 
with FDA Good Laboratory Practice regulations (21 CFR Part 58) and the CPMP guidance 
documents (CPMP/ SWP/ 465/ 95 and CPMP/ ICH 302/ 95). Groups of 20 rabbits (10 female 
and 10 male; 80 total for the study) were immunized with one of four formu lations including a 
high-dose (100 µg) of protein alone, a mid -dose of [ADDRESS_138106] dose  levels  were  selected  based on  intended mid -dose 
and high -dose to be used in human Phase I trials.  
In this GLP study there were no findings definitively attributed to systemic toxicity of Sm -p80 
with or without  GLA -SE. All study  animals  survived  until scheduled  humane  termination.  There 
were no changes in body weights, body temperatures, or food consump tion attributed to Sm - 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138107] to local tolerance, injection site observations were generally similar throughout the 
study for male and female rabbits in groups receiving Sm -p80 with or without GLA -SE. Th ere 
were sporadic grades of 1 (very slight) and 2 (slight) edema at the injection site for rabbits in all 
[ADDRESS_138108] in rabbits of both sexes that received  injections containing both the high 
dose of Sm -p80 (100 μg) with adjuvant (10 μg GLA -SE). Low doses of Sm -p80 plus adjuvant 
(10 μg GLA -SE) produced higher titers than high dose (100 μg) of Sm -p80 alone justifying the 
use of the adjuvant. There were no maj or histopathological findings in animals humanely 
terminated 2 days following the fourth (final) administration. Slight increases in fibrinogen and 
C-reactive protein were observed in treatments groups on Day 24.  
This toxicity  study  indicated  that the SchistoShield®  vaccine  is safe and well tolerated  in rabbits 
when administered IM for up to four injections at the highest proposed human dose of the Sm - 
p80 antigen given with GLA -SE. No significant local or systematic toxicity was found. As 
previously report ed, general safety assessment of the SchistoShield® vaccine in baboons also 
indicated that the vaccine is safe and well tolerated for up to the highest dose of 250 µg of Sm - 
p80 and 50 µg of GLA -SE, further supporting the observation from the GLP -toxicity study in 
rabbits. Based on the N+1 rule, the GLP -toxicity study in rabbits supports the use of the 
SchistoShield® vaccine in the first -in-human clinical trial for up to three injections at the high 
dose of 100 µg Sm -p80 .  
 
Scientific  Rationale  
2.2.1 Purpose  of Study  
The promising results of the preclinical evaluations and the urgent need for an effective 
schistosomiasis vaccine support advancement of the SchistoShield® vaccine candidate to an 
initial Phase [ADDRESS_138109] formulation, on Days 1, 29, and 57 (28 
days apart) or on a delayed boos ter dose schedule on Days 1, 29, and 180.  
To determine  the need  for adjuvant,  the study  will evaluate  one group  of subjects  who receive 
the Sm-p80 antigen  without  adjuvant  (Group  A). The [ADDRESS_138110] antigen content proposed for administration with adjuvant in this trial (Group E).  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138111],  at doses  of 10 μg, 30 μg, and 100 μg Sm-p80, 
adjuvanted with 5 μg of the GLA -SE adjuvant. The GLA -SE formulation has been used as a 
vaccine adjuvant in 13 clinical trials (seasonal and pandemic influenza, leishmaniasis, 
schistosomiasis,  malaria,  tuberculosis).  Approximately [ADDRESS_138112] one 
study injection containing GLA -SE, with GLA doses ranging from 0.5 to 20.0 µg. This vaccine 
adjuvant  is well-tolerated  with generally  only mild local  and systemic  adverse  events  (AEs)  and 
no significant AEs related to the product. The adjuvant dose of 5 µg is selected for this trial as 
this dose is in the mid-range  of doses  evaluated,  has been  shown  to increase  antibody  levels  and 
cellular immune responses, and has been evaluated in mul tiple clinical trials, including trials 
administering three vaccinations, demonstrating an acceptable safety profile.  
The preclinical studies of SchistoShield® do not inform the selection of antigen dose for this 
study, as non -human primates require much h igher doses of antigen and adjuvant than humans 
due to the tolerizing effects of their environments. In the baboon studies, the animals that 
received active study product were given three injections, four weeks apart, of a formulation of 
[ADDRESS_138113] to elicit T 
cell responses  while  the higher  doses  tend to elicit  better  humoral  responses.  Since  it appears  that 
the primary  mechanism  of action  of SchistoShield®  is mediated  by [CONTACT_122795],  this study 
will evaluate a range of Sm -p80 doses from 10 to 100 µg.  
Study Groups A, B, D, and E will receive study vaccinations on a Day 1, 29 and 57 schedule (28 
days between vaccinations) while Study Group C will receive study vaccinations on a Day 1, 29 
and 180 delayed booster schedule. The comparison of the same vaccine formulation, 30 μg Sm - 
p80 + [ADDRESS_138114] 
been associated with enhanced immunogenicity, for example with H5 influenza vaccines given 
as a two-dose series  either  28 days or 180 days apart[22]  and for recombinant  hepatitis  B vaccine 
given on a 0, 1, and 2 month versus a 0, 1, and 6 month schedule.[23]  
2.2.[ADDRESS_138115] feeding a child.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138116]  lie down  with legs elevated.  Bruising  at the blood  draw  site may 
occur but can be prevented or lessened by [CONTACT_119911] a few 
minutes after the blood is taken. IM injection may also cause transient discomfort and fainting. 
Drawing  blood  and IM  injection  may cause  infection.  The use of aseptic  (sterile)  technique  will 
make infection at the site where blood will be drawn or where the study vaccination will be 
given extremely unlikely.  
 
There  is a small  amount of  risk to subjects  who report  that they are in good health  but who have 
an un known health problem at the time of screening. This trial will screen by [CONTACT_117145], 
medical  history,  vital signs,  and clinical  laboratory  tests,  including WBC,  hemoglobin,  platelets, 
and ALT, as well as screening for HIV, hepatitis B, and hepatitis C infections.  
 
For this first -in-human trial of the SchistoShield® vaccine there is no human safety data with 
which to estimate the potential risks of the study product formulatio ns to be evaluated in this 
trial. Preclinical evaluations, including evaluations in non -human primates, have not identified a 
safety  signal  associated  with administration  of the Sm-p80 recombinant  protein  antigen  (Sections 
[IP_ADDRESS] and 2.1.5 ). 
 
There  is potential  for AEs to occur  more  frequently  in the adjuvanted  vaccine  groups [24]  than in 
the non -adjuvanted group and there is potentially a higher risk for AEs to occur more frequently 
in the higher dose Sm -p80 antigen groups than in the lower dose antigen groups. GLA -SE 
adjuvant has been evaluated in humans with other vaccine antigens and  has been found to have 
an acceptable safety profile, as described in Section 2.1.[ADDRESS_138117] been noted in preclinical 
evaluations and in one human clinical trial, in which GLA -SE was formulated with the Fluzone 
influenza vaccine.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138118]  as skin rash (hives),  swelling  around  the mouth,  throat,  or eyes (angioedema),  difficulty 
breathing (bronchospasm), a fast pulse (tachycardia), or decrease in blood pressure 
(hypotension). If these reactions occur, they can usually be stopped by [CONTACT_122796]. As with any vaccine or medication, there is a 
very small chance of a death, although researchers do not expect this to occur.  
 
Subjects will be asked to provide protected health information (PHI). All attempts will be made 
to keep this PHI confide ntial within the limits of the law. However, there is a chance that 
unauthorized persons will see the subject’s PHI. All study records will be kept in a locked file 
cabinet or maintained in a locked room at the study site. Electronic files will be password - 
protected. Only people who are involved in the conduct, oversight, monitoring, or auditing of 
this trial will be allowed access to the PHI that is collected. Any publications from this trial will 
not use information that will identify subjects by [CONTACT_2300]. O rganizations that may inspect and/or 
copy  research  records  maintained  at the participating  sites for quality  assurance  and data analysis 
include groups such as the local IRB, NIAID, and the FDA.  
 
A description  of this clinical  trial will be available  on http://www.ClinicalTrials.gov,  as required 
by [CONTACT_122797]. This web site will not include information that can identify subjects.  
 
There  may be other  risks,  discomforts,  or side effects  that are unknown  at this time.  
 
2.3.[ADDRESS_138119]  benefit  to subjects  resulting  from  participation  in this trial. 
There  is potential  benefit  to society  by [CONTACT_122798].  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  35  
  
 
 
 
STUDY  DESIGN,  OBJECTIVES  AND  ENDPOINTS  OR 
OUTCOME MEASURES  
 
Study  Design  Description  
This is a Phase  1, open -label,  dose-escalation  clinical  trial to evaluate  the safety,  reactogenicity, 
and immunogenicity of the Sm -p80 + GLA -SE candidate schistosomiasis vaccine 
(SchistoShield®) in healthy adults 18 through 55 years of age. The Sm -p80 antigen is a 
recombinant protein produced in E. coli and GLA -SE is an immunological adjuva nt. 
Five treatment groups, each including nine subjects, will receive three intramuscular (IM) 
injections of 0.[ADDRESS_138120] on either Days 1, 29, and 57 or on Days 1, 
29, and 180 (Table  1). Group  A (unadjuvanted  comparator)  will receive 100  μg Sm-p80 alone  on 
Days 1, 29, and 57, Group B (low dose standard schedule) will receive 10 μg Sm -p80 + 5 μg 
GLA -SE on Days 1, 29 and 57, Group C (mid dose delayed booster) will recei ve 30 μg Sm -p80 
+ 5 μg GLA -SE on Days 1, 29 and 180, Group D (mid dose standard schedule) will receive 30 
μg Sm -p80 + 5 μg GLA -SE on Days 1, 29, and 57, and Group E (high dose standard schedule) 
will receive  100 μg Sm-p80 + [ADDRESS_138121] -vaccination interval, only SAEs, medically attended 
adverse events (MAAEs), new onset chronic medical conditions (NOCMCs), and potentially 
immune -mediated medical conditions (PI[INVESTIGATOR_106279]) will be collected. Clinic al laboratory 
evaluations for safety will be performed on venous blood collected prior to, and approximately 
seven days after, each study vaccination.  
Immunogenicity  testing  will include  measuring  titers  of total IgG against  the Sm-p80 protein  by 
[CONTACT_6428]. Ge ne expression will be evaluated using RNA Seq analysis from whole blood.  
For additional  details  on study  procedures  and evaluations  and study  schedule  by [CONTACT_122799]/days, see Sections 6 and 7 and Table 8  and Table 9 . 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  36  
  
 
 
Study  Objectives  
3.2.1 Primary  
• To assess  the safety  and reactogenicity  following  receipt  of three  doses  of 1) 100 µg Sm-p80 
(unadjuvanted),  2) 10 µg Sm-p80 + 5 µg GLA -SE, 3) 30 µg Sm-p80 + 5 µg GLA -SE, and 4) 
100 µg Sm-p80 + 5 µg GLA -SE administered  intramuscularly  on Days  1, 29, and 57 and 5) 
30 µg Sm-p80 + 5 µg GLA -SE administered  on Days  1, 29, and 180. 
3.2.2 Secondary  
• To assess  anti- Sm-p80 IgG antibody  responses  from  samples  collected  at specified  time 
points.  
3.2.3 Exploratory  
• To assess  innate  and adaptive  immune  signatures  from  samples  collected  at specified  time 
points.  
 
Study  Endpoints  or Outcome  Measures  
3.3.1 Primary  
• Occurrence  of study  vaccine -related  SAEs  from  the time of the first study  vaccination 
through approximately [ADDRESS_138122] study vaccination.  
• Occurrence  of solicited  injection  site and systemic  reactogenicity  events  from  the time of 
each study vaccination through 7 days after each study vaccination.  
• Occurrence  of clinical safety  laboratory  AEs from  the time of each study  vaccination  through 
approximately 28 days after each study vaccination.  
• Occurrence  of all unsolicited  AEs,  regardless  of the assessment  of seriousness  or relatedness, 
from the time of each study vaccination through 28 days after each study vaccination.  
• Occurrence  of SAEs,  MAAEs,  NOCMCs,  and PI[INVESTIGATOR_122737] [ADDRESS_138123] study vaccination.  
3.3.2 Secondary  
• For Sm -p80 IgG antibodies, number of subjects achieving seroconversion, defined as a 
fourfold  rise from  baseline,  at approximately  [ADDRESS_138124]  study 
vaccinations.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  37  
  
 
 
• Geometric  mean  titers  of serum  Sm-p80 IgG antibodies  from  samples  collected  at [ADDRESS_138125] vaccination.  
3.3.3 Exploratory  
• Identification  and characterization  of gene  expression  changes  as measured  using  RNA -seq 
analysis from whole blood relative to last vaccination.  
o Days  8 and 29 vs. Day 1, and  Day 36 vs. Day 29 for all study  groups  
o Day 57 vs. Day 29, Day 64 vs. Day 57 for Groups  A, B, D, and E 
o Day 187 vs. Day 180 for Group  C 
• Identification  and characterization  of gene  expression  changes  as measured  using  RNA -Seq 
relative to last vaccination that correlate with peak Sm -p80 IgG antibody levels.  
o Days  8 and 29 vs. Day 1, and Day 36 vs. Day 29 for all study  groups  
o Day 57 vs. Day 29, Day 64  vs. Day 57 for Groups  A, B, D, and E 
o Day 187 vs. Day 180 for Group  C 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  38  
  
 
 
 
STUDY  INTERVENTION/INVESTIGATIONAL 
PRODUCT  
 
Study  Product  Description  
The vaccine  product  is a two-component  system  comprised  of Sm-p80 antigen  and GLA -SE 
adjuvant.  
Sm-p80 for injection  
Sm-p80 is a recombinant protein  produced  in E. coli bacteria.  The protein  antigen  is the large 
subunit of the S. mansoni calcium -activated neutral protease, calpain. The Sm -p80 protein is 
formulated and lyophilized to yield t he vaccine antigen, Sm -p80 for Injection. The final [ADDRESS_138126] formulated in a SE to produce GLA -SE. 
Sm-p80 + GLA -SE 
Sm-p80 + GLA -SE contains the antigen and adjuvant. After  reconstitution of the  antigen with 
water -for-injection  (WFI)  and mixing  with the liquid  adjuvant,  it is ready  for administration  to 
the study participant.  
4.1.1 Formulation,  Packaging,  and Labeling 
Sm-p80 for Injection  
Sm-p80 for Injection  is formulated  as a lyophilized  cake in glass  vials  and appears  white  to off- 
white cake. Each 3 mL glass vial contains 125 µg of Sm -p80. Reconstitution of Sm -p80 with 
WFI results in a clear, colorless solution. Vials are for single -use only.  
GLA -SE Adjuvant  
GLA -SE Adjuvant is formulated as 20 µg/mL GLA in a 4% SE and is suppli ed as single use 
glass  vials.  GLA -SE appears  as a milky -white  liquid.  Each  2 mL vial contains  a fill volume  of 
0.4 mL. 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  39  
  
 
 
Sm-p80 + GLA -SE for Injection  
Sm-p80 for Injection and GLA -SE adjuvant are added to each other in a 1:1 ratio and mixed by 
[CONTACT_122800][INVESTIGATOR_122738].  This yields  a 2% oil emulsion  with GLA  at 10 
µg/mL and Sm -p80 at the desired concentration for the various dose levels of the antigen. After 
mixing, the dissolved Sm -p80 antigen and the GLA -SE emulsion appears as a translucent milky 
white liquid.  
Sterile  Water  for Injection,  USP 
The sterile WFI is nonpyrogenic and contains no bacteriostatic, antimicrobial agent or added 
buffer.  This product  will be used to dilute  the vaccine  (Sm-p80) and will be supplied  as a single - 
dose vial.  
Each study product (Sm -p80 and GLA -SE) will be labeled according to manufacturer and 
regulatory  specifications  and include  the statement:  “Caution:  New  Drug -Limited  by [CONTACT_52632].”  
4.1.[ADDRESS_138127]  be stored  between  2°C to 8°C; excursions  up to 25°C  are permitted 
for [ADDRESS_138128] be stored between 2°C to 8°C; excursions up to 
25°C are permitted, but the product should never be frozen. cGMP adjuvant lots have been on a 
stability  program  for over 5 years  and are stable  for this period  when  properly  stored  at 2°C to 8°C. 
Sm-p80 + GLA -SE for Injection  
The vaccine product (antigen + adjuvant) is only produced upon admixture prior to 
administration.  A syringe  stability  study  was completed  to confirm  stability  of the admixture  for 
at least 4 hours at up to 25°C.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  40  
  
 
 
Sterile  Water  for Injection,  USP 
The sterile  WFI vials  are stored  at 20°C  to 25°C  [See USP Controlled  Room  Temperature].  
 
Acquisition/Distribution  
Sm-p80 for Injection  
Sm-p80 for Injection  will be provided  by [CONTACT_122801] (CMS), Fisher BioServices.  
GLA -SE Adjuvant  
The GLA -SE adjuvant  is purchased  from  a commercial  supplier  (IDRI)  and distributed  through 
the DMID Clinical Material Services (CMS), Fisher BioServices.  
Sterile  Water  for Injection,  USP 
The sterile  WFI,  USP will be supplied  by [CONTACT_122802],  Fisher  BioServices.  
 
Dosage/Regimen,  Preparation,  Dispensing  and Administration  of 
Study Intervention/Investigational Product  
 
Preparation  
Study product preparation, including vaccine dilutions, and admixing for the various dosing 
groups, will be performed by [CONTACT_122803] a biological 
safety cabinet or laminar flow hood on the same day of study vaccine adm inistration. See the 
protocol -specific  MOP  for detailed  information  on the preparation,  labeling,  and storage  of study 
product for each Study Group.  
The research pharmacist will visually inspect the study products upon receipt and prior to use. If 
the study product(s)  appear(s)  to have  been  damaged,  contaminated  or discolored,  contain  visible 
particulate matter or if there are any concerns regarding its integrity, the pharmacist will not use 
the affected study product(s). The affected study product(s) will be quarantined as per storage 
requirements  and labeled  as ‘Do Not Use’  (until  further  notice).  The site PI [INVESTIGATOR_122739] (see MOP for contact [CONTACT_3031]) 
and DMID Clinical Project Manager for further instructions before any additional study 
vaccinations are administered. Based on the information collected, DMID a nd/or the 
manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the site will receive specific instructions on how to return the affected study product(s) to  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138129] information are provided in the 
protocol -specific MOP.  
For Groups B, C, D, and E the Sm -p80 will be appropriately formulated and mixed with diluted 
GLA -SE adjuvant. Group A participants will receive Sm -p80 (diluted to the appropriate 
concentration) without adjuvant. Once diluted, the unadjuvanted Sm -p80 vaccin e must be used 
within [ADDRESS_138130] be  used within 4 hours of 
preparation. The four -hour window begins when the final formulated preparation is mixed and 
drawn into a syringe for administration to a study partici pant. The time of preparation and time 
of administration should be noted in the source documentation. Both the diluted vaccine and 
vaccine  plus adjuvant  admixture  will be held at 2°C to 25°C.  Study  product  will be administered 
within [ADDRESS_138131] 
for each group.  Each  dose of study  vaccine  will be administered  as a single 0.5  mL IM injection 
in the  deltoid muscle of the participant’s arm.  
Participants will be observed in the clinic for a minimum of [ADDRESS_138132] symptoms and to inform 
investigators immediately if they experience symptoms that may require medica l attention.  
Participants  may be instructed  to return  to the clinic  if they feel febrile  on any individual  day or 
if they develop any severe reactions following vaccination.  
 
Accountability  Procedures  for the Study  Intervention/Investigational 
Product(s)  
Once  received,  study  products will  be stored  in and dispensed  by [CONTACT_122804].  
The Food and Drug Administration (FDA) requires accounting for the disposition of all 
investigational products. The Investigator is responsible for ensuring that a current record of 
product disposition is maintained, and product is dispensed only at an off icial study site by 
[CONTACT_122805].  Records  of product  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138133]  to inspection  by a regulatory 
agency (e.g., the FDA) at any time. An assigned Study Monitor will review the pharmacy 
records.  
Unused reconstit uted investigational product vials will be stored at 2°C to 25°C in the 
Investigational  Pharmacy  until clinical  trial accountability  is completed.  At study  termination,  all 
unused  investigational  product  will be disposed  in accordance  with the MOP  followin g complete 
drug accountability and monitoring.  
 
Modification  of Study  Intervention/Investigational  Product  for a 
Participant  
The study  product  will be administered  to enrolled  participants  according  to the study  schedule. 
There is no planned modification of a study product administration for participants, with the 
exception that participants who have received a study product injection and who become 
ineligible  for further  study  product  injections  (Section  5.2.1 ) will be precluded  from  these  study 
procedures. Every effort will be made to follow vaccinated participants for safety evaluations.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138134]  Inclusion/Exclusion  Criteria  in DMID -sponsored  studies. 
Questions abo ut eligibility will be directed toward the DMID Medical Officer.  
 
Eligibility  Criteria  
5.1.[ADDRESS_138135]  meet  all of the following  inclusion  criteria  to be eligible  for enrollment  in this 
study.  
1. Male  or non-pregnant  female  18 through  55 years  of age, inclusive,  at the time of consent.  
2. Able  and willing  to participate  for the duration  of the study  and able to understand  and comply 
with planned study procedures.  
3. Able  and willing  to provide  written  (not proxy)  informed  consent.  
 
4. Is in good  health,  as judged  by [CONTACT_093],  and determined  by [CONTACT_122806]*.  
* Existing medical diagnoses or conditions (except those in the Subject Exclusion 
Criteria)  must  be deemed  as stable.  A stable  medical  condition  is defined  as no change  in 
prescription medication, dose, or frequency of medication in the last three months (90  
days) and health outcomes of the specific disease are considered to be within acceptable 
limits in the last six months (180 days).  Any change due to change of health care 
provider, insurance company, or that is done for financial reasons, as long as in th e same 
class of medication, will not be considered a violation of this inclusion criterion.  Any 
change in prescription medication due to improvement of a disease outcome, as 
determined by [CONTACT_7880] [INVESTIGATOR_29353] -investigator, will not be considered a 
violation of this inclusion criterion.  Subjects may be on chronic or as needed (prn) 
medications if, in the opi[INVESTIGATOR_122740] -investigator, they pose no 
additional risk to subject safety or assessment of solicited events and immun ogenicity.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  44  
  
 
 
Topi[INVESTIGATOR_2855],  nasal,  and inhaled  medications  (with  the exception  of some  uses of 
corticosteroids  as outlined  in the Subject  Exclusion  Criteria),  vitamins,  and 
contraceptives are permitted.  
5. Women  of childbearing  potential*  must  have  a negative  serum  pregnancy  test at screening 
and a negative urine pregnancy test within [ADDRESS_138136] injection.  
*Not  sterilized  via bilateral  tubal  ligation,  bilateral  oophorectomy,  or hysterectomy,  or, if 
menopausal, stil l menstruating or < [ADDRESS_138137]  used an acceptable  form  of contraception*  in the 
[ADDRESS_138138] injection.  
*Acceptable single forms of contraception include abstinence from  sexual activity that 
could lead to pregnancy, monogamous relationship with vasectomized partner who has 
been vasectomized for six months or more prior to enrollment, successful Essure® 
placement (permanent, non -surgical, non -hormonal sterilization), intra uterine devices, 
and hormonal methods, including the birth control patch, shot (Depo -Provera), pi[INVESTIGATOR_3353], the 
vaginal  ring (NuvaRing),  and the contraceptive  implant  (Nexplanon).  Acceptable  barrier 
methods include diaphragm or cervical cap with spermicide and the contraceptive 
sponge.  
7. Women  of childbearing  potential  must  agree  to continue  use of an acceptable  form  of 
contraception through [ADDRESS_138139] injection.  
8. Weight  ≥50 kg and body  mass  index  (BMI)  < 35.0 kg/m2 
9. Vital  signs  (oral  temperature,  pulse,  and blood  pressure)  are all within  normal  protocol - 
defined ranges.* 
* The normal protocol -defined ranges for vital signs include (a) oral temperature less 
than 38°C  (100.4°F),  (b) pulse  no greater  than 100 bpm,  (c) systolic  blood  pressure  85 to 
150 mmHg, inclusive, and (d) diastolic BP ≤ 100 mmHg.  
10. Screening  clinical  lab values  are all within  normal  protocol -defined  reference  ranges.  
*The  normal  protocol -defined  ranges  for laboratory  tests include  (a) ALT  of < 47 IU/L,  
(b) creatinine less than or equal to the laboratory upper limit of normal, (c) WBC ≥3.80 
x103/UL and ≤13.00 x103/UL, (d) hemoglobin 11.5 g/dL or greater for females or 12.6 
g/dL  or greater  for males,  (e) platelets  between  131 x103/UL and 415 x103/UL, inclu sive. 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138140] injection.  
5. Asthma,  other  than mild,  well-controlled  asthma*  
*Cold  or exercise -induced  asthma  controlled  with inhaled  medications  other  than inhaled 
corticosteroids is permissibl e. Subjects should be excluded if they require daily 
bronchodilator use, or have had an asthma exacerbation requiring oral/parenteral steroid 
use or have used theophylline or inhaled corticosteroids in the past year  
6. Known  atherosclerotic  cardiovascular  disease  or history  of myocardial  infarction, 
pericarditis, or myocarditis.  
7. Diabetes  mellitus  
8. History  of a psychiatric  condition  that may make  study  compliance  difficult,  such as 
schizophrenia, or poorly controlled bipolar disorder*  
*Includes  persons  with psychoses  or history  of suicide  attempt  or gesture  in the 3 years 
before study entry or an ongoing risk for suicide.  
9. Chronic  or active  neurologic  condition  (including  seizures*  and migraine  headaches**).  
*Seizure  within  the past 5  years  
**Four  or more  migraine  headaches  in the past [ADDRESS_138141] 5 years  that required  emergency  or 
inpatient medical care.  
10. Autoimmune disease*  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  46  
  
 
 
*Autoimmune  hypothyroidism  with or without  replacement  therapy,  and vitiligo  or mild 
eczema or psoriasis not requiring chronic therapy, are permissible.  
11. Known or suspected congenital or acquir ed immunodeficiency including anatomic or 
functional  asplenia*  or immunosuppression  as a result  of underlying  illness  or treatment.  
*Any  splenectomy  is exclusionary.  
12. Use of alcohol  or drugs  that, in the opi[INVESTIGATOR_1072],  may interfere  with ability  to 
comply with the protocol or increase risk to subject’s health during the study period.  
13. Active  neoplastic  disease*  
*Subjects  with a history  of malignancy  may be included  if treated  by [CONTACT_122807],  or 
by [CONTACT_122808] a period that in the 
investigator’s estimation provides a reasonable assurance of sustained cure (not less than 
36 months).  Cervical  neoplasia  under  surveillance and  non-melanoma  skin cancer  are not 
exclusionary.  
14. Chronic  topi[INVESTIGATOR_122741]* 
*Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons using a topi[INVESTIGATOR_122742] a limited  duration  for mild uncomplicated  dermatitis  such as poison  ivy 
or contact [CONTACT_122809] t heir therapy is 
completed. Oral or parenteral (intravenous, IM, subcutaneous) corticosteroids given for 
non-chronic conditions not expected to recur are permissible if, within the year prior to 
enrollment, the longest course of therapy was no more than [ADDRESS_138142] 30 days prior to enrollment. T opi[INVESTIGATOR_122743].  
15. Known  contraindication  to repeated  phlebotomy*  
*Such  as minimal  venous  access  or recent  history  of anemia  
16. Receipt  or planned  receipt  of inactivated  vaccine  or allergy  desensitization  injection  within 
[ADDRESS_138143] injection.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138144] injection.  
19. Receipt  of any experimental  agent*  within  [ADDRESS_138145] study visit**.  
*Vaccine,  drug,  biologic, device,  blood  product,  or medication.  
**Receipt  of experimental  COVID -19 related  products  are not necessarily  exclusionary 
and will be evaluated on a case -by-case basis.  
20. Plan to undergo  surgery  (elective  or otherwise)  within  six months  after study  enrollment.  
21. Plans  to enroll  in another  interventional clinical  trial* at  any time during  the study  period.  
*Includes  trials  evaluating  interventions  such as a drug,  biologic,  or device.  
22. Positive  confirmatory  test for HIV infection.  
23. Positive  serologic  test for hepatitis  B surface  antigen  (HBsAg).  
24. Positive  confirmatory  test for hepatitis  C virus  (HCV)  infection.  
25. Acute  febrile  illness  (oral  temperature  ≥ 38°C)  or other  acute  illness  within  three  days prior 
to study product injection.*  
*Note  for afebrile,  acute  illness  only:  If a subject is afebrile,  his/her  acute  illness  is nearly 
resolved with only minor residual symptoms remaining, and, in the opi[INVESTIGATOR_122744] -investigator, the residual symptoms will not interfere with the ability 
to assess safety parameters as required by [CONTACT_760], the subject may receive study 
product injection without further approval from the DMID Medical Officer.  
26. Not willing  to avoid  donating  blood  during  the study.  
27. Has any condition  that would,  in the opi[INVESTIGATOR_122745],  place  the subject  at an 
unacceptable risk of injury or render the subject unable to meet the requirements of the 
protocol.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138146] be recorded in the 
electronic case report forms (eCRFs).  
The reasons,  might  include,  but are not limited  to the following:  
• Subject  meets  individual  haltin g criteria  (specified in  Section  8.6.2 ). 
• Subject develops a medical disease or condition, or new clinical finding(s) for which 
continued  participation,  in the opi[INVESTIGATOR_122746], interfere with the subject's successful completion of this study, or interfere with the 
evaluation of responses.  
• The study  is terminated.  
• Presence  of signs  or symptoms  that could  confound  or confuse  assessment  of study  product 
reactogenicity.  
• As deemed  necessary  by [CONTACT_7880] [INVESTIGATOR_122747]-investigator  for noncompliance  or 
other reasons.  
• Subject  refuses further  study  product  injections.  
• Subject  withdraws  consent.  
• Subject  lost to follow -up. 
The primary  reason  for withdrawal  from  this trial will be recorded  on the Study  Status eCRF. 
Subjects will be encouraged to complete the Early Termination Visit. The Early Termination 
Visit procedures are listed in Section 6.3.[ADDRESS_138147]  will be encouraged  to 
remain in this trial for follow -up safety assessments (which may be conducted by [CONTACT_122810]  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  49  
  
 
 
rather than in person) continuing through approximately [ADDRESS_138148] study vaccination. See the protocol -specific MOP for alternate follow -up requirements.  
 
The investigator should be explicit regarding study follow -up (e.g. safety follow -up) that might 
be carried o ut despi[INVESTIGATOR_122748].  If the subject 
consents, every attempt will be made to follow all AEs through resolution.  The procedures that 
collect  safety  data for the purposes  of research  must  be inclusive  in the original  informed  consent 
form (ICF) or the investigator may seek subsequent informed consent using an IRB -approved 
ICF with the revised procedures.  
 
In the case of subjects who fail to appear for a follow -up safety assessment, efforts (i. e., three 
documented contact [CONTACT_122811] a 
certified  letter)  will be made  to locate  or recall  them,  or at least to  determine  their health  status. 
These efforts will be documented in the subject’s stud y records.  
 
The investigator  will inform  the subject  that already  collected  data will be retained  and analyzed 
even if the subject withdraws from this study.  
5.2.[ADDRESS_138149] may be replaced.  
5.2.3 Study  Termination  
The NIAID  has the right  to terminate  this study  at any time.  Reasons  for terminating  the study 
may include, but are not limited to, the following:  
• Incidence  or severity  of AEs indicating  a potential  health  hazard.  
• Data  recording  is inaccurate  or incomplete.  
• The Investigator  has not adhered  to the protocol  or applicable  regulatory  guidelines  in 
conducting the study.  
 
In addition,  the study  may be discontinued  at the discretion  of the U.S. FDA  or the study  site, or 
due to natural disaster.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  50  
  
 
 
If the study is prematurely terminated by [CONTACT_456], any regulatory authority, or the 
investigator  for any reason,  the investigator  will promptly  inform  the study  subjects  and assure 
appropriate  therapy  or follow -up for the subjects, as  necessary.  The investigator  will provide  a 
detailed written explanation of the termination to the IRB.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  51  
  
 
 
 
STUDY  PROCEDURES  
 
The Schedules  of Events  are included  as Table  7, Table  8, and Table  9 in Appendix  A. Refer  also 
to Section 4 and Section 8. 
Clinical  assessment  of subjects  may be performed  by [CONTACT_122812] 1572 as the s ite PI [INVESTIGATOR_1660] a sub -investigator.  
 
Screening,  Visit  00 (Day  -30 to Day -1) 
All subjects will have a screening visit in the [ADDRESS_138150] injection 
visit.  Screening  laboratory  evaluations  with abnormal  values  may be repeated  during  this period 
only as specified in Section 7.2.1 . 
Subjects  who are not enrolled  within  the 30-day window  after the screening  visit may be 
rescreened to refresh the window.  
Writt en informed consent will be obtained prior to conducting any screening procedures. A 
single  consent  form  will be used to document  consent  to screening  and to participation  in the 
study.  
The following  procedures  will be performed  at the initial  screening  visit (Table  7): 
• Subjects  will be provided  with a description  of this trial (purpose  and study  procedures)  and 
asked to read and sign the ICF. The ICF will be signed prior to perfor ming any study 
procedures, including any screening procedures.  
• Demographic  information  will be obtained  by [CONTACT_122813].  
• Eligibility  criteria  will be reviewed  with subjects and  eligibility  assessed  by [CONTACT_122814].  
• A complete medical history will be obtained and all concomitant medications taken in the 
prior [ADDRESS_138151] study vaccination.  
• Vital  signs,  including  oral temperature,  blood  pressure,  and pulse,  will be obtained  to ensure 
eligibility. Subjects must not eat or drink anything hot or cold, or sm oke, within 10 minutes 
prior to oral temperature measurement.  
• Height  and weight  will be obtained  to calculate  BMI.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  52  
  
 
 
• A physical examination that assesses general appearance and the following areas/systems: 
skin, lymph nodes, HEENT (head, ears, eyes, nose, and throat), neck, cardiovascular, 
pulmonary,  abdomen,  extremities,  musculoskelet al, and neurological,  will be performed  by a 
study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the 
site PI [INVESTIGATOR_11637] -investigator.  
• Venous  blood  will be collected  for screening  laboratory  tests (WBC,  hemoglobin,  platelets, 
creatinine,  ALT,  HIV-1/HIV -[ADDRESS_138152] for 
female subjects of childbearing potential) in volumes as specified in Table 7 . 
• HIV test counseling  will be provided.  
• For women of childbearing potential, contraceptive methods will be reviewed to ensure 
eligibility,  recent  menstrual  history  will be obtained,  and pregnancy  avoidance  counseling 
will be provided.  
The following  procedures  will be performed  if the screening  visit is repeated  to re-screen  the 
subject if they are not enrolled within the 30 -day window:  
• Eligibility  criteria  will be reviewed  with subjects  and eligibility assessed  by [CONTACT_122814].  
• A complete medical history will be obtained and all concomitant medications taken in the 
prior [ADDRESS_138153] study vaccination.  
• Vital  signs,  including  oral temperature,  blood  pressure,  and pulse,  will be obtained  to ensure 
eligibility. Subjects must not eat or drink anything hot or cold, or smoke, within 10 minutes 
prior to oral temperature measurement.  
• If indicated, a  targeted  physical  examination  will be performed.  
• Venous blood will be collected for screening labora tory tests (WBC, hemoglobin, platelets, 
creatinine,  ALT,  and pregnancy  test for female  subjects  of childbearing  potential)  in volumes 
as specified  in Table  7. Testing  for HIV-1/HIV -2, anti-HCV antibody,  and HBsAg  should  be 
repeated only if the previous testing was more than six months earlier.  
• For women of childbearing potential, contraceptive methods will be reviewed to ensure 
eligibility,  recent  menstrual  history  will be obtained,  and pregnancy  avoidance  counseling 
will be provided.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138154]  injection,  the following  procedures  will be performed:  
• Medical  history  and concomitant  medications will  be reviewed.  
• A targeted  physical  examination  will be performed  by a study  clinician  licensed  to make 
medical  diagnoses  and listed  on the Form  FDA  1572  as the site PI  [INVESTIGATOR_11637]-investigator,  if 
indicated by [CONTACT_9870].  
• Vital  signs,  including  oral temperature,  blood  pressure,  and pulse,  will be obtained  to ensure 
eligibility and establish baseline. Subjects must not eat or drink anything hot or cold, or 
smoke, within 10 minutes prior to or al temperature measurement.  
• Inclusion/exclusion  criteria,  including  the results  of all clinical  screening  laboratory 
evaluations, will be reviewed to verify eligibility  
• For women of childbearing potential, contraceptive methods will be reviewed to ensure 
eligibility,  recent  menstrual  history  will be obtained,  pregnancy  avoidance  counseling  will be 
provided, and a urine pregnancy test will be performed. A test performed on a sample 
obtained within [ADDRESS_138155] be negative.  
• A pre-administration  reactogenicity  assessment  will be performed  to establish  baseline.  
• Venous blood samples will be obtained for safety labs, PBMC isolation, and immunologic 
assays  in volumes  as specified  in Table  8, for Groups  A, B, D, and E, and Table  9 for Group  
C. The clinical  safety  laboratory  results  will not be available  or reviewed  prior  to study 
vaccination.  
• The assigned  study  product  will be administered  IM injection  in the deltoid  muscle  of the 
preferred arm. The site of injection (right or left arm) and time of administration will be 
recorded on the appropriate eCRF.  
• Subjects  will be observed  in the clinic  for at least [ADDRESS_138156] -administration reactogenicity assessments will be performed, and 
any AE or SAE will be recorded on the appropriate eCRF prior to discharge from the clinic.  
• Subjects will be provided with a web -based electronic Memory A id (e-Memory Aid) or  
Paper Memory Aid and thermometer for recording daily maximum oral temperature,  
solicited  injection  site and systemic  reactions,  unsolicited  AEs,  and concomitant  medications, 
beginning on the evening of Day 1 and continuing daily for th e next 7 days. Subjects will be  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  54  
  
 
 
encouraged to take their temperature around the same time each day and also if they feel 
feverish.  Subjects  will be instructed  on how to use the memory  aid and how to rate any AEs.  
Subjects  will be instructed  to notify  the study  center  if they develop  any severe  reactions  and/or 
fever equal to or exceeding 38.0°C (100.4°F). If the investigator deems the reaction warrants 
further evaluation or intervention, the investigator will give further instructions on the proper 
course of action, including a return to the clinic for im mediate evaluation if appropriate.  
 
Planned  Study  Visits  
The second  study  product  injection  will be administered  at Visit  05, Day 29 (window  ± 3 days).  
The third  study  product  injection  will be administered  at Visit 08,  Day 57 (window  ± 3 days)  for 
subjects in Groups A, B, D, and E and will be administered at Visit 09, Day [ADDRESS_138157]  injection:  
• For a subject  to receive  the study  product  injection,  Individual  Halting  Criteria  will be 
reviewed (refer to Section 8.6.2 ). 
 
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic  diseases,  and symptoms  suggestive  of a MAAE/NOCMC/PI[INVESTIGATOR_106286],  will be obtained 
by [CONTACT_122815].  
 
• All concomitant  medications  will be recorded  on the appropriate  eCRF,  if known  and not 
previously collected.  
• All newly  identified  AEs/SAEs/MAAEs/NOCMCs/PI[INVESTIGATOR_122749].  
 
• Vital  signs,  including  oral temperature,  pulse,  and blood  pressure,  will be obtained  prior  to 
the study product injection. Subjects must not eat or drink anything hot or cold, or smoke 
within 10 minutes prior to taking oral temperature.  
 
• A targeted physical examination, including an assessment for signs suggestive of a 
MAAE/NOCMC/PI[INVESTIGATOR_106286], may be p erformed, if indicated based on review of interim 
medical  history,  by a study  clinician  licensed  to make  medical  diagnoses  and listed  on the 
Form FDA 1572 as the site PI [INVESTIGATOR_11637] -investigator.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  55  
  
 
 
• For women of childbearing potential, contraceptive methods will be reviewed to ensure 
eligibility,  recent  menstrual  history  will be obtained,  pregnancy  avoidance  counseling  will be 
provided, and a urine pregnancy test wi ll be performed. A test performed on a sample 
obtained within [ADDRESS_138158] be negative.  
• Pre-administration  reactogenicity  assessments  will be performed  to establish  baseline.  
 
• Venous blood samples will be obtained for clinical safety labs, PBMC isolation, and 
immunologic assays, in volumes as specified in Table [ADDRESS_138159]  via IM injection  into the deltoid  muscle 
of the  preferred arm.  
• The second or third study product injections may be given in the same arm as the previous 
study  product  injection  as long as there  is no interference  with the reactogenicity  assessment. 
The site of injection (right or left arm) and time of administration will be recorded on the 
appropriate eCRF. Subjects will be observed in the clinic for at least 30 minutes after the 
study vaccination. The injection site will be examined, pos t-administration reactogenicity 
assessments will be performed, and any AE/SAEs will be recorded on the appropriate eCRF 
prior to discharge from the clinic.  
• Subjects  will be provided  with an e-Memory  Aid or Paper  Memory  Aid and thermometer  for 
recording dai ly maximum oral temperature, solicited injection site and systemic reactions, 
unsolicited AEs, and concomitant medications, beginning on the evening of the  day of study 
product injection and continuing daily for the next seven days. Subjects will be encour aged 
to take their temperature around the same time each day and also if they feel feverish. 
Subjects will be instructed on how to use the memory aid and how to rate any AEs.  
• Subjects will be instructed to notify the study center if they develop any severe  reactions 
and/or fever equal to or exceeding 38°C (100.4°F). If the investigator deems the reaction 
warrants  further  evaluation  or intervention,  the investigator  will give further  instructions  on 
the proper course of action, including a return to the clin ic for immediate evaluation if 
appropriate.  
6.3.[ADDRESS_138160] study 
vaccination.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  56  
  
 
 
6.3.2 Early  Termination  Visit  
 
The following activities will be performed at the early termination visit on subjects who 
withdraw,  or are withdrawn  or terminated  from  this trial and who are willing  to participate  in the 
visit, clinical evaluations, and study procedures:  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions  and symptoms 
suggestive  of a MAAE/NOCMC/PI[INVESTIGATOR_106286],  will be obtained  by [CONTACT_122816].  
 
• Memory  Aid information  will be reviewed  with subjects  (if within  [ADDRESS_138161] study 
vaccination).  
 
• All concomitant  medications  will be recorded  on the appropriate  eCRF  (if within  [ADDRESS_138162] injection).  
 
• AEs will be assessed  and recorded  as described  in Section  3.1. 
 
• Vital  signs,  including  oral temperature,  pulse,  and blood  pressure,  may be obtained  if 
clinically indicated.  
 
• A targeted physical examination, including an assessment for signs suggestive of a 
MAAE/NOCMC/PI[INVESTIGATOR_106286], may be performed, if indicated based on review of interim 
medical  history,  by a study  clinician  licensed  to make  medical  diagnoses  and listed  on the 
Form FDA 1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• The study  vaccination  site will be examined  (if within seven  days after the last study  product 
injection).  
 
• Post-administration  reactogenicity  assessments  will be performed  (if within  seven  days after 
the last study product injection).  
 
• Approximately  8.5 mL of venous  blood  will be collected  for serum  antibody  assays  (if within 
[ADDRESS_138163] study vaccination).  
 
• Approximately 7 mL of venous blood will be collected for clinical safety labs (WBC, 
hemoglobin,  platelets,  ALT,  and creatinine),  and performed  by [CONTACT_122817] [ADDRESS_138164] study vaccination.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  57  
  
 
 
Unscheduled  Study  Visits (if  needed)  
Participants  may be asked  to come  in for additional  clinic  visits  if, for example,  the need  arises 
for follow -up of local or systemic AE such as febrile illnesses, or for requests for repeat blood 
draws for scheduled laboratory testing from the  clinical laboratory due  to sample  hemolysis or 
clotting.  
A supplemental  visit eCRF  will be filled  and signed  by [CONTACT_122818].  All unscheduled 
visits will be entered into Emmes’ Advantage eClinical® internet data entry system on the 
appropriate eCRFs. Please see the MOP for details.  
 
Protocol  Deviations  
 
A protocol devi ation is any noncompliance with the clinical trial protocol, GCP, or protocol - 
specific MOP requirements.  The noncompliance may be either on the part of the subject, the 
investigator, or the study site staff.  As a result of deviations, corrective actions s hould be 
developed by [CONTACT_3483].  It is the responsibility of the site PI [INVESTIGATOR_122750].  All 
individual protocol deviations will be addressed in subje ct study records.  All protocol 
deviations, either individual, product, or site -specific will be collected and the record stored in a 
sponsor -determined  location.  Protocol  deviations  must  be sent to the IRB per its guidelines.  The 
site PI [INVESTIGATOR_122751].  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138165], liver, pancreas, 
kidney, urologic system, nervous system, blood, lymph nodes, endocrine system, 
musculoskeletal system, skin, and genital/reproductive tract. A history of any allergies, cancer, 
immunodeficiency, psychiatric illness, s ubstance abuse, and autoimmune disease will be 
solicited.  At follow -up visits  after the first study  vaccination,  an interim  medical  history  will be 
obtained by [CONTACT_122819]. 
The interim medical history should include an assessment for new medical conditions and 
symptoms suggestive of a MAAE/NOCMC/PI[INVESTIGATOR_106286].  
 
Concomitant  medications  will be collected  as described  in Section  7.1.[ADDRESS_138166]’s interim medical history, by a study clinician licensed to make 
medical  diagnoses  and listed  on the Form  FDA  1572  as the site PI [INVESTIGATOR_11637]-investigator.  Targeted 
physical examinations should also include an assessment for signs suggestive of a 
MAAE/NOCMC/PI[INVESTIGATOR_106286].  
 
Vital  signs  (oral  temperature,  pulse,  and blood  pressure)  will be collected  at the screening  visit, 
at vaccination visits, and at clinic visits sc heduled within [ADDRESS_138167] injection, which 
includes an assessment of injection site reactions including pruritus, erythema, induration/ 
swelling, pain, and tenderness as well as systemic reactions inclu ding fever, chills, fatigue, 
malaise, myalgia, arthralgia, headache, and nausea or vomiting. Pre -administration  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138168] -administration reactogenicity assessments will be 
performed, and any AE/SAEs will be recorded on the appropriate eCRF prior to discharge from 
the clinic.  The injection  site will also be examined  approximately  [ADDRESS_138169] Memory Aids will be reviewed with the 
subjects  for AEs (solicited  injection  site and systemic  reactions  and unsolicited  AEs) during  each 
post-injection clinic or phone visit through 7 days after the injection.  
 
7.1.1 Assessment  of Concomitant  Medications/Treatments  other  than  Study  Product  
 
Administration of any medications, therapi[INVESTIGATOR_014], or vaccines will be recorded on the appropriate 
eCRF. Concomitant medications will include all current medications and medications taken in 
the [ADDRESS_138170] vaccination and those taken from the ti me of vaccination through 
approximately 28 days after  each vaccination, as described in Section 3.1. Medications reported 
in the electronic case report form (eCRF) are limited to those taken w ithin [ADDRESS_138171](s) should not 
be used during the trial -reporting period (approximately [ADDRESS_138172] study 
vaccination) unless clinically indicated as part of the subject’s health care. Medication s in this 
category include the prohibited medications per the Subject Exclusion Criteria (see Section 
5.1.2 ). In addition,  the site PI [INVESTIGATOR_122747]-investigator  may identify  other  medications  that 
should not be used due to a risk to subject safety or assessment of reactogenicity and 
immunogenicity.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  60  
  
 
 
Laboratory  Evaluations  
7.2.1 Clinical  Laboratory  Evaluation s 
 
Subjects will be screened for HIV -1 and HIV -2 infection by a fourth -generation testing 
algorithm,  for HCV  infection,  and for HBsAg.  Screening  labs also include  WBC,  hemoglobin, 
platelets, creatinine, and ALT.  
 
Serum (screening visit) and urine (study product injection visits) pregnancy tests will be 
performed.  Serum  pregnancy  tests will be performed  by [CONTACT_122820]. 
Urine pregnancy CLIA -waved tests will be performed by [CONTACT_122821].  Pregnancy  testing  will be done  at the screening  visit and within 
[ADDRESS_138173] injection.  
 
Clinical  safety  laboratory  parameters  (WBC,  hemoglobin,  platelets,  ALT,  and creatinine)  will be 
collected from each subject on the day of and prior to each study product injection, 
approximately [ADDRESS_138174] injection (which may also serve as the clinical safety labor atory samples for the 
second and/or third study product injection). These evaluations will be performed by [CONTACT_122822]. Venous blood samples will be collected for these safety labs. The results from the 
clinical safety laboratory parameters collec ted on the day of study product injections will not be 
available or reviewed prior to study product injection.  
 
Laboratory values that are outside the range of eligibility but are thought to be due to an acute 
condition or due to laboratory error may be re peated once. One or more of the laboratory 
parameters may be repeated at any time during the study as determined by [CONTACT_978], if indicated by 
[CONTACT_1149]. A clinically  significant  abnormal  value  should  be repeated  within  10 days if possible  and 
followed up as clinically relevant.  
 
The volume  of venous  blood  to be collected  for the clinical  safety  laboratory  evaluations  is 
presented in Table 8  and Table 9.  
 
7.2.2 Research  Assays  
The research  assays  to be performed for  the immunologic  endpoints  are specified  below.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  61  
  
 
 
[IP_ADDRESS]  ELISA  (anti  Sm-p80 IgG)  
Vaccine -specific  IgG antibody  responses  will be assessed  by [CONTACT_122823] (8.5 ml of blood collected in a serum separator tube) at specific time points selected to 
evaluate the kinetics of the response after each administration, peak response, and durability, 
including prior to each vaccination on the day of vaccin ation, at [ADDRESS_138175] the Sm -p80 protein. Briefly, thawed serum 
samples are serially diluted (12 dilutions at 4 -fold each) using robotic liquid handlers on 
duplicate  384-well plates.  The serially  diluted  sera are transferred  and incubated  on ELISA  plates 
coated with Sm -p80 protein. Appropriate standards (pooled participant sera) and controls will be 
included for plate quality control based on criteria established during prior optimizations.  
Following,  secondary  antibody  (HRP -conjugated)  incubation,  plates  will be developed  and read 
at OD 450 -570nm. Endpoint titer will be calculated for each curve and duplicates will be 
averaged if within established variance limits.  
[IP_ADDRESS]  RNA -Seq 
RNA Sequencing (RNA -Seq) will be performed  by [CONTACT_122824]. Novogene will perform total RNA extraction, RNA 
quantification and qualification, library preparation, Illumina whole -transcriptome sequencing, 
and raw data quality checking.  Novogene will transfer the raw FASTQ files to Emmes. Emmes 
will perform RNA -Seq data analyses, including pre -alignment sequence quality control, 
reference alignment, post -alignment quality control, gene expression quantification, differential 
gene  express ion analyses,  gene  cluster  and pathway  analyses,  as well as predictive  modeling  (see 
Section 10.5.4).  
[IP_ADDRESS]  Laboratory  Specimen  Preparation,  Handling,  and Storage  
 
Instructions  for specimen  preparation,  handling,  and storage  are included  in the laboratory 
manual and protocol -specific MOP as appropriate.  
 
[IP_ADDRESS]  Laboratory  Specimen  Shippi[INVESTIGATOR_122752].  Specimen 
labeling requirements will also be included in the study MOP.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  62  
  
 
 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  63  
  
 
 
 
ASSESSMENT  OF SAFETY  
 
Assessing  and Recording  Safety  Parameters  
Safety  will be assessed  by [CONTACT_122825]: 
 
1. SAEs  occurring  from  the time of the first study  product  injection  through  the end of follow - 
up which is approximately [ADDRESS_138176] injection.  
 
2. Solicited  AEs – reactogenicity  events  occurring  from  the time of each study  product  injection 
through [ADDRESS_138177] injection:  
 
a) Injection  site reactions  including  pruritus,  erythema,  induration/swelling,  pain,  and 
tenderness.  
 
b) Systemic  reactions  including  fever,  chills,  fatigue,  malaise,  myalgia,  arthralgia,  headache, 
nausea, and vomiting.  
 
3. Clinical  safety  laboratory  AEs assessed  as described  in Section  7.2.1 . Parameters  to be 
evaluated include WBC, hemoglobin, platelets, ALT, and creatinine.  
 
4. Unsolicited  AEs – non-serious  AEs occurring  from  the time of each study product  injection 
through [ADDRESS_138178] 
injection.  
 
8.1.1 Adverse  Events  (AEs)  
The International Conference on Harmonisation (ICH) E6 defines an AE as any untoward 
medical  occurrence  in a patient  or clinical  investigation  subject  administered  a pharmaceutical 
product  regardless  of its causal  relationship  to the study  treatment.  The FDA  defines  an AE as 
any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered  drug related.  
An AE can therefore  be any unfavorable  and unintended  sign (including  an abnormal  laboratory 
finding), symptom, or disease temporally associated with the use of medicinal (investigational) 
product.  The occurrence of an AE may come to the attention of study personnel during study  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  64  
  
 
 
visits  and interviews  of a study  recipi[INVESTIGATOR_122753],  or upon  review  by a study 
monitor.  
All AEs, including solicited local (injection site) and systemic (subjective and quan titative) 
reactions, will be captured on the appropriate eCRF.  Information to be collected for AEs 
includes event description, date of onset, assessment of severity, relationship to study product 
and alternate  etiology  (assessed  only by [CONTACT_122826]  a diagnosis 
and listed on the Form FDA 1572 as an investigator), date of resolution, seriousness and 
outcome.  AEs occurring during the trial collection and reporting period will be documented 
appropriately regardless of relat ionship.  AEs will be followed through resolution.  
Any medical  condition  that is present  at the time that the subject  is screened  will be considered 
as baseline and not reported as an AE.  However, if the severity of any pre -existing medical 
condition increa ses, it should be recorded as an AE.  
If an event  meets  both the criteria  of a study  endpoint  and an AE,  the event  will be reported 
either as a study endpoint or as an AE (not both).  
[IP_ADDRESS]  Adverse  Events  Grading  
All AEs (laboratory and clinical symptoms) will be graded for severity and assessed for 
relationship to study product (see definitions). AEs characterized as intermittent require 
documentation  of onset  and duration  of each epi[INVESTIGATOR_1865].  The start and stop date of each reported 
AE will be recorded on the appropriate eCRF.  
Severity  of Event:  
AEs will be assessed  by [CONTACT_122827] -defined  grading system specified  in 
Section  8.1.2  and Appendix  C. For events  not included  in the protocol -defined  grading  system, 
the following guidelines will be used to quantify severity:  
• Mild (Grade 1) : Events that are usually transient and may require only minimal or no 
treatment  or therapeutic  intervention  and generally  do not interfere  with the subject’s  usual 
activities of daily living.  
• Moderate (Grade 2) : Events that are usually alleviated with addit ional specific therapeutic 
intervention.  The event  interferes  with usual  activities  of daily  living,  causing  discomfort  but 
poses no significant or permanent risk of harm to the research participant.  
• Severe (Grade 3) : Events interrupt usual activities of daily living, or significantly affects 
clinical  status,  or may require  intensive  therapeutic  intervention.  Severe  events  are usually 
incapacitating.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138179]: The assessment of the relationship of an AE to the 
administration of study product is made only by [CONTACT_122828] t raining and authority to make a 
diagnosis  and listed  on the Form  FDA  [ADDRESS_138180] 
will be assessed for AEs using the terms related or not related:  
• Related  – There  is a reasonable  possibility  that the study  product  caused  the AE.  Reasonable 
possibility means that there is evidence to suggest a causal relationship between the study 
product and the AE.  
• Not Related  – There  is not a reasonable  possibility  that the administration  of the study 
product caused the event.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  66  
  
 
 
8.1.2 Reactogenicity  
Reactogenicity events are AEs that are known to occur with this type of study vaccine. The 
following  Toxicity  Grading  Scales  will be used to grade  solicited  local  (injection  site) and systemic 
(subjective and quantitative) reactions:  
Table  3: Injection  Site Reactogenicity  Grading  
 
Local  (Injection  Site) 
Reaction   
Mild  (Grade  1)  
Moderate  (Grade  2)  
Severe  (Grade  3) 
 
Pain – experienced 
without touching the 
injection site 
(spontaneous  discomfort)   
Subject is aware of pain 
but it does not interfere 
with daily  activity  and no 
pain medication is taken  Subject  is aware  of pain; 
there  is interference  with 
daily activity or it 
requires use of pain 
medication   
 
Subject  is aware  of pain and 
it prevents  daily  activity  
 
 
Tenderness  – hurts  only 
when injection site is 
touched or the arm is 
moved  The area immediately 
surrounding  the injection 
site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily 
activity   
The area immediately 
surrounding the injection 
site hurts  when  touched  or 
with arm motion, and it 
interferes with  daily 
activity   
The area immediately 
surrounding the injection 
site hurts  when  touched  or 
with arm motion, and it 
prevents daily activity  
 
Pruritus  (itching)  Does  not interfere  with 
daily activity  Interferes  with daily 
activity   
Prevents  daily  activity  
 
Swelling*  Does  not interfere  with 
daily activity  Interferes  with daily 
activity   
Prevents  daily  activity  
* Will be also measured  in cm but size will not be used as halting  criteria.  
 
 
Table  4: Injection  Site Reactogenicity  Measurements  
 
Local  (Injection  Site) 
Reaction   
Small  (Grade  1) Medium  (Grade 
2)  
Large  (Grade  3) 
Erythema  (Redness)*  2.5 – 5 cm 5.1 – 10 cm > 10 cm 
Induration 
(Hardness)/Swelling*   
2.5 – 5 cm  
5.1 – 10 cm  
> 10 cm 
* Will not be used as halting  criteria.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  67  
  
 
Table  5: Subjective  Systemic  Reactogenicity  Grading  
 
Systemic  (Subjective)  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
 
Chills  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
Myalgia (Body 
Aches/Muscular  Pain)*  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Arthralgia  (Joint  Pain)*  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Nausea  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Vomiting  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Headache  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Malaise  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Fatigue  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
* Not at injection  site 
 
 
Oral temperature# will be graded  as follows:  
Table  6: Quantitative  Systemic  Reactogenicity  Grading  
 
Systemic  (Quantitative)  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
Fever*  - oral† 38.0°C  – 38.4°C  
100.4°F  – 101.1°F  38.5°C  – 38.9°C  
101.2°F  – 102.0°F  >38.9°C  
>102.0°F  
# Oral temperature  assessed  on Day 1 (Visit  01) before  the first study product  injection will  be considered  as 
baseline.  
*Note:  A fever  can be considered  not related  to the study  product  if an alternative  etiology  can be documented.  
† Subjects  must  not eat or drink  anything  hot or cold,  or smoke  within  10 minutes  before  taking  oral temperature.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  68  
  
 
8.1.3 Serious  Adverse  Events  (SAEs)  
An AE or suspected  adverse  reaction  is considered an  SAE  if, in the view  of either  the site 
principal investigator [INVESTIGATOR_10157], it results in any of the following outcomes:  
• death,  
• a life-threatening  AE*,  
• inpatient  hospi[INVESTIGATOR_40088],  
• a persistent  or significant  incapacity  or substantial  disruption  of the ability  to conduct  normal 
life functions, or  
• a congenital  anomaly/birth defect.  
• important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical judgment 
they may jeopardize  the patient  or subject  and may require  medical  or surgical  intervention  to 
prevent one of the outcomes listed in this definition.  Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatie nt hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.  
*Life-threatening AE. An AE is considered “life -threatening” if, in the view of either the site 
principal  investigator  [INVESTIGATOR_10157],  its occurrence  places  the patient  or subject  at imme diate  risk of 
death.  It does not include an AE that, had it occurred in a more severe form, might have caused 
death.  
SAEs  will be: 
• Assessed  for severity  and relationship  to study  product  and alternate  etiology (if  not related 
to study product) by a licensed study physician listed on the Form FDA 1572 or by [CONTACT_122829] [INVESTIGATOR_54720] -Investigator.  
• Recorded  on the appropriate  SAE  data collection  form  and eCRF.  
• Followed through resolution by a licensed study physician (for Investigational New Drug 
Application  [IND]  studies,  a physician  listed  on the Form  FDA  1572  as the site PI [INVESTIGATOR_54720]- 
Investigator).  
• Reviewed  and evaluated  by [CONTACT_122830],  the DSMB  or SMC  (periodic  review  unless  related),  and 
the IRB/IEC.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  69  
  
 
 
 
Specification  of Safety  Parameters  
Safety  will be assessed  by [CONTACT_122825]: 
8.2.[ADDRESS_138181].  
8.2.3 New -Onset  Chronic  Medical  Conditions  (NOCMCs)  
NOCMCs are defined as any new ICD -[ADDRESS_138182] 3 
months and requires continued health care inte rvention.  
8.2.4 Medically -Attended  Adverse  Events  (MAAEs)  
Defined  as a hospi[INVESTIGATOR_059],  ER visit,  or an otherwise  unscheduled  visit to or from  medical 
personnel for any reason; and considered related to study product.  
8.2.5 Potentially  Immune -Mediated  Medical  Conditio ns (PI[INVESTIGATOR_106279])  
PI[INVESTIGATOR_122754]  a group  of AEs that includes  diseases  which  are clearly  autoimmune  in 
etiology and other inflammatory and/or neurologic disorders which may or may not have 
autoimmune etiologies. PI[INVESTIGATOR_122755] B  List of 
PI[INVESTIGATOR_106279].  
 
Report ing Procedures  
8.3.1 Reporting  Serious  Adverse  Events  
SAEs  will be followed  until resolution  even  if this extends  beyond  the study -reporting  period. 
Resolution of an AE is defined as the return to pretreatment status or stabilization of the 
condition with the ex pectation that it will remain chronic.  
Any AE (including  MAAEs,  NOCMC,  and PI[INVESTIGATOR_106279])  that is considered  an SAE  must  be 
submitted  immediately  (within  24 hours  of site awareness)  on an SAE  form  to the DMID 
Pharmacovigilance Group, at the following address:  
DMID  Pharmacovigilance  Group  
Clinical  Research  Operations  and Management  Support  (CROMS)  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138183]. Suite  650 
Bethesda, MD [ZIP_CODE], [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] (US) or 1 -[PHONE_1728] (outside US)  
SAE  FAX  Number:  [PHONE_2620]  (US)  or [PHONE_2621]  (outside  US) 
SAE  Email  Address:  [EMAIL_1393]  
In addition  to the SAE  form,  select  SAE  data fields  must  also be entered  into the  DCC  system. 
Please see the protocol -specific MOP for details regarding this procedure.  
Other  supporting  documentation  of the event  may be requested  by [CONTACT_122831].  
The DMID  Medical  Monitor  and DMI D Clinical  Project  Manager  will be notified  of the SAE  by 
[CONTACT_71500].  The DMID Medical Monitor will review and assess the 
SAE for regulatory reporting and potential impact on study subject safety and protocol conduct.  
At any time after completion of the study, if the site principal investigator [INVESTIGATOR_29353] - 
investigator  becomes  aware  of an SAE  that is suspected  to be related  to study  product,  the site 
principal investigator [INVESTIGATOR_29353] -investigator will re port the event to the DMID 
Pharmacovigilance Group.  
8.3.[ADDRESS_138184] a causal 
relationship  between  the study  intervention  and the AE. DMID  will submit  an IND safety  report 
to the FDA and will notify the site PI  [INVESTIGATOR_122756], as soon as possible.  DMID will report to the FDA any unexpected fatal or life - 
threatening suspected adverse reaction as soon as possible, but in no case later than 7 calendar 
days after the sponsor’s initial receipt of the information.  If the event is not fatal or life - 
threatening the IND safety report will be submitted within 15 calendar days after the sponsor 
determines that the information qualifies for reporting as specified in 21 CFR Part 312.32.  
Relevant  follow  up information  to an IND safety  report  will be submitted  as soon  as the 
information is available.  
 
All SAEs  designated  as “not related”  to study  product(s),  will be reported  to the FDA  at least 
annually in a summary format.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138185]’s permission all protocol -required venous blood sam ples will be obtained 
and the subject  will continue  to be followed  for safety  for the duration  of this trial. Efforts  will be 
made to follow all pregnancies reported during the course of this trial to pregnancy outcome 
pending the subject’s permission.  
 
The pregnancy will be documented on the Pregnancy Reporting Form provided by [CONTACT_52634], and 
this form will be used for the pregnancy event data entry into Advantage eClinical. All study 
mandated blood samples will be obtained and the participant will continue in follow -up for 
safety events. Pregnancies will be followed until 30 days after delivery to determine outcome, 
including  spontaneous  or voluntary  termination,  details  of the birth,  and the presence  or absence 
of any birth defects, congenital abnormalities , or maternal and/or newborn complications. No 
subsequent product injections will be administered to pregnant participants.  
8.3.4 Disclosure  of Study  Related  Information  
 
Subjects  can choose  to receive  written  disclosure  of their treatment  assignment  after the database 
has been locked.  
 
Type  and Duration  of Follow -up of Subjects  after  Adverse  Events  
AEs will be assessed  and followed  from  initial  recognition  of the AE through  end of the protocol 
defined follow -up period.  
SAEs  will be followed  up through  resolution  even  if duration  of follow -up goes beyond  the 
protocol -defined follow -up period.  
Resolution  of an AE is defined  as the return  to pre-treatment  status  or stabilization  of the 
condition with the expectation that it will remain chronic.  
 
Follow-up procedures,  evaluations,  and outcomes  will be recorded  on the appropriate  data 
collection form.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138186] Values or Abnormal Clinical Findings  
The site PI [INVESTIGATOR_122757] -investigator is responsible for reporting all AEs/SAEs that are 
observed  or reported  during  the study,  regardless  of the relationship  to study  product.  AEs/SAEs, 
abnormal clinical laboratory test values, or abnormal clinical findings will be documented, 
reported and followed appropriately.  
Clinical safety laboratory results from specimens obtained after the first study product injection 
will be graded  as indicated  in the Toxicity  Tables  in Appendix  C. Clinical  laboratory  evaluations 
assessed  on the day of and prior  to the first study  product  injection  (Day  1) will  be considered as 
baseline.  
Systolic  and diastolic  blood  pressures  obtained  following  vaccination  will be defined  as AEs and 
graded as indicated in the Toxicity Tables in Appendix C below . However, baseline  values prior 
to the first vaccination, including values obtained at the screening visit and at Visit 1 prior to 
vaccine administration, may meet the inclusion criteria of systolic blood pressure 85 to 150 
mmHg, inclusive, but fall within values defined as Grade 1 severity in the Toxicity Table.  
Similarly, baseline values may meet the inclusion criteria of diastolic blood pressure ≤ [ADDRESS_138187]  administration.  
• Any death  occurring  within  [ADDRESS_138188].  
• Any subject  experiences  ulceration,  abscess,  or necrosis  at the injection  site considered 
related to study product administration.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  73  
 
 
 
 
• Any subject  experiences  laryngospasm,  bronchospasm,  or anaphylaxis  within  [ADDRESS_138189].  
• Two or more  subjects  experience  generalized  urticaria  within  [ADDRESS_138190].  
• Any other  SAE  deemed  to be related  to study  product  based  on close  temporal  relationship  or 
other factors.  
• Three  or more  subjects  in the same  dose/schedule  study  group  discontinue  study  product 
injections due to AEs.  
• Three  or more  subjects  develop  same  Grade  [ADDRESS_138191].  
The study  will also be halted  for SMC  review/recommendation  if, within  [ADDRESS_138192], any of the following occurs:  
•  Two or more  subjects  experience  the same  Grade  [ADDRESS_138193] -related  injection  site 
reaction (excluding the size of erythema and swelling/induration).  
•  Two or more  subjects  experience  the same  Grade  [ADDRESS_138194] -related  subjective 
systemic reaction, for which the severity (grade) is corroborated by [CONTACT_3462].  
•  Two or more  subjects  experience  the same  Grade  [ADDRESS_138195] -related  quantitative 
systemic reaction.  
•  Two or more  subjects  experience  the same  Grade  [ADDRESS_138196] -related  laboratory 
abnormality.  
Grading  scales  for solicited  injection  site and systemic  (subjective  and quantitative)  reactions  are 
included in Section 8.1.[ADDRESS_138197] 
during the entire trial, as applicable.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138198] injections if 
AEs that meet  the halting  criteria  are reported.  Similarly,  the PI [INVESTIGATOR_113961],  using  discretion,  ask for the 
study to be placed on hold and an SMC meeting to be held for any single event or combination  
of multiple  events  which, in the  PI’s professional opi[INVESTIGATOR_1649],  jeopardize  the safety  of the subjects  or 
the reliability of the data.  
8.6.[ADDRESS_138199]  injections  will be discontinued  in an individual  if: 
• The subject  has a systemic  hypersensitivity  reaction  following  a study  product  injection  that 
is judged related to the study product  
• The subject  has ulceration,  abscess,  or necrosis  at the injection  site related  to study  product 
administration.  
• Presence  of signs  or symptoms  that could  confound  or confuse  assessment of  study  vaccine 
reactogenicity. For subjects with injection site or systemic signs or symptoms, or with an 
acute illness, including an oral temperature greater than or equal to 37.8°C, on the day of a 
scheduled  study  product  injection,  the study  product  injection  should  be postponed/deferred 
until the signs, symptoms, or acute illness have resolved, or are improving as further 
specified below, and if within the acceptable protocol -specified window for that visit No 
exceptions to the protocol -specified window will be made.  
Note for afebrile, acute illness only: If a subject is afebrile, has an acute illness that is 
nearly resolved with only minor residual symptoms remaining, is still within the acceptable 
protocol -specified  window  for the study  product  injection  and, in the opi[INVESTIGATOR_122758] -investigator, the residual symptoms will not interfere with the ability to 
assess safety parameters as required by [CONTACT_760], the subject may receive the study 
product  injection  without  further  approval  from  the DMID  Medical  Officer.  No exceptions  to 
the protocol -specified window will be made.  
• Any clinically  significant  medical  condition  that, in the opi[INVESTIGATOR_122759] -investigator, poses an additional risk to the subject if they continue to 
participate in the study.  
• Grade  3 clinical  safety  laboratory  value  (according  to the Toxicity  Tables  Appendix  C) that 
does not decrease to Grade [ADDRESS_138200] injection. The subsequent study  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138201]  injection  should  be scheduled  to occur  within  the acceptable  protocol -specific 
window for that visit.  No exceptions to the protocol -specified window will be made.  
• Severe  or sustained  reaction  or disability  relate d to prior  administration  of study  product.  
8.6.[ADDRESS_138202],  given on  Days  1, 
29, and 57 or on Days 1, 29, and 180. Dose escalation will proceed as described in the Protocol 
Summary. If one or more dose escalation stoppi[INVESTIGATOR_122760] n should proceed.  
• Any subject  develops  a Grade  [ADDRESS_138203].  
• Three  or more  subjects  in the most  recently  enrolled  study  group  develop  the same  Grade  [ADDRESS_138204].  
• Three  or more  subjects  develop  the same  Grade  [ADDRESS_138205].  
• Any subject  has an event  meeting  an individual  halting  criterion.  
 
Safety  Oversight  
This clinical  study  will utilize  an SMC,  which  is an independent  group  of experts  that advises  the 
DMID. The primary responsibility of the  SMC  is to monitor subject safety. The  SMC is external 
to the DMID and comprises at least three voting members. The SMC will consist of members 
with appropriate phase [ADDRESS_138206] an ad hoc SMC meeting through DMID.  
The SMC  will review  cumul ative  safety  data at time points  that may include  but not limited  to: if 
dose escalation criteria are not met, if halting criteria are met, on an ad hoc basis if a potential 
safety concern is identified, at least annually for safety data review, or for fin al safety data 
review after completion of the study safety follow -up. These activities will be delineated in the 
SMC charter.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138207]/Independent  Ethics  Committee  
 
The site principal investigator [INVESTIGATOR_122761] -site trial will obtain IRB approval for this protocol 
to be conducted at the research site and send supporting documentation to the DMID before 
initiat ing recruitment  of subjects.  The investigator will  submit  applicable  information  to the IRB 
on which it relies for the review, to conduct the review in accordance with 45 CFR 46, ICH E6 
GCP, and as applicable, 21 CFR 56 (Institutional Review Boards) and 21  CFR 50 (Protection of 
Human Subjects), other federal, state, and local regulations. The IRB must be registered with 
Office  of Human  Research  Protection  (OHRP)  as applicable  to the research.  DMID  must  receive 
the documentation that verifies IRB approval fo r this protocol, associated informed consent 
documents, and upon request any recruitment material and handouts or surveys intended for the 
subjects, prior to the recruitment and enrollment of subjects.  
 
Any amendments to the protocol or consent materials will be approved by [CONTACT_12228].  IRB review and approval will occur at least annually throughout the 
enrollment and follow -up of subjects and may cease if annual review is no longe r required by 
[CONTACT_122832].  The investigator  will notify  the IRB of  deviations  from  the 
protocol and reportable SAEs, as applicable to the IRB policy.  
 
Each  institution  engaged  in this research  will hold a current FWA  issued  by [CONTACT_12230].  
 
Informed  Consent  Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing  throughout  the individual’s  trial participation.  Before  any study  procedures 
are performed, informed consent will be obtained and documented.  Subjects will receive a 
concise and focused presentation of key information about the  clinical trial, verbally and with a 
written consent form. The explanation will be organized an d presented in lay terminology and 
language that facilitates understanding why one might or might not want to participate.  
An investigator or designee will describe the protocol to potential subjects face -to-face. The key 
information  about  the purpose  of the study,  the procedures  and experimental  aspects  of the study, 
risks and discomforts, any expected benefits to the subject, and alternative treatment will be 
presented first to the subject.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  77  
  
 
 
Subjects  will also receive  an explanation  that the trial involves  research,  and a detailed  summary 
of the proposed study procedures and study interventions/products.  This will include aspects of 
the trial that are experimental,  any expected benefits, all possible risks (including a statement 
that the particular treatment or procedure may involve risks to the subject or to the embryo or 
fetus, if the subject is or may b ecome pregnant, that are currently unforeseeable), the expected 
duration of the subject’s participation in the trial, alternative procedures that may be available 
and the important potential benefits and risks of these available alternative procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes 
available that may be relevant to their willingness to continue participation in the trial. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are 
available if injury occurs, and, if so, what they consist of, or where further information may be 
obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject 
for participating in the trial, a s well as any anticipated prorated payments, if any, to the subject 
for participating  in the trial. They  will be informed  of whom  to contact  (e.g.,  the investigator)  for 
answers to any questions relating to the research project.  
Information will also inclu de the foreseeable circumstances and/or reasons under which the 
subject’s participation in the trial may be terminated. The subjects will be informed that 
participation  is voluntary  and that they are free to withdraw  from  the study  for any reason  at any 
time without penalty or loss of benefits to which the subject is otherwise entitled.  
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed. Subjects will be informed 
that the monitor(s), auditors(s), IRB, NIAID, and regulatory a uthority(ies) will be granted direct 
access  to the subject’s  original  medical  records  for verification  of clinical  trial procedures  and/or 
data without  violating  the confidentiality  of the subject,  to the extent  permitted  by [CONTACT_122833], and that, by [CONTACT_2960] a written ICF, the subject is authorizing such access.  
Subjects will be informed that records identifying the subject will be kept confidential, and, to 
the extent permitted by [CONTACT_29695]/o r regulations, will not be made publicly 
available and, if the results of the trial are published, the subject’s identity will remain 
confidential.  Subjects  will be informed  whether  private  information  collected  from  this research 
and/or specimens will be used for additional research, even if identifiers are removed.  
Subjects will be allowed sufficient time to consider participation in this research trial and have 
the opportunity  to discuss  this trial with their family,  friends  or legally  authorized  representative, 
or think about it prior to agreeing to participate.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138208](s) for their records.  The subject(s) 
may withdraw consent at any time through out the course of the trial.  The rights and welfare of 
the subject(s)  will be protected  by [CONTACT_122834].  
Study personnel may employ recruitment efforts prior to obtaining study consent if the IRB has 
agreed that persons identified from a patient database (of Kaiser Permanente Washing ton) may 
be sent recruitment materials, and - if interested - receive further information about the study by 
[CONTACT_122835]. If the IRB has agreed, persons interested in participating in the study who are 
presumptively eligible by [CONTACT_122836]. If that review does not identify exclusionary 
information,  a screening  clinic  visit would  be scheduled.  At that visit,  research  staff would  obtain 
written consent per the standard informed consent process before conducting protocol -specific 
screening activities.  
New  information  will be communicated  by [CONTACT_122837]  [INVESTIGATOR_122762].  The informed  consent  document 
will be updated and subjects will be re -consented per IRB requirements, if necessary.  Subjects 
will be given a copy of all ICFs that they sign.  
9.2.1 Requirements  for Permission  by [CONTACT_122781]/Guardians and  Assent  by [CONTACT_63779]  (in 
case of a minor)  
Not applicable.  
9.2.[ADDRESS_138209] Research is the re -use of identifiable data or identifiable 
biospecimens  that were  collected  from  some  other  ‘‘primary’’  or ‘‘initial’’  activity,  such as the 
data and samples collected in this protocol. This section will detail the samples and data  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  79  
  
 
 
available  for secondary  research.  Any use of the secondary  sample or data,  however,  will be 
presented in a separate protocol and require separate IRB approval.  
9.3.2 Samples  for Secondary  Research  
Residual samples/specimens are those that are left over after protocol -specified testing and this 
study has been completed. As a condition of study participation, subjects agree that residual 
samples  will be stored  coded  indefinitely  at the DMID  CMS.  On completion  of the trial, residual 
specimens may be shared with investigators at the participating site and with other investigators 
at other institutions. The recipi[INVESTIGATOR_122763] a 
NIH certificate of confidentiality. The information p rovided to the recipi[INVESTIGATOR_122764].  
Samples will be stored indefinitely at a DMID -designated storage facility. Each sample will be 
encoded (labeled) only with a barcode and a unique tracking number to protect subject 
confidentiality. Secondary research with coded samples and data may occur, however, subject 
confidentiality  will be maintained  as described  for this protocol.  An IRB review  of the secondary 
research using coded specimens is required.  
Residual/Repository  Research  Samples,  upon  written  request  and approval  from  DMID  and any 
approva ls required by [CONTACT_122838], may be shared for secondary research with 
investigators at the participating site, with researchers at other Infectious Disease Clinical 
Research Consortium (IDCRC) sites or other institutions, or company -designated rese arch 
laboratories. The samples will not be sold or used directly for production of any commercial 
product. DMID will authorize shipment from the DMID CMS.  
TTUHSC may receive serum samples and PBMC before the final database lock. The serum 
samples  can be aliquoted  and stored  for secondary  research.  The PBMC may  be received  and 
stored for secondary research. TTUHSC will not evaluate the samples until after the final 
database lock and approval received from DMID and the IDCRC per the IDCRC secondary 
research policy.  
Reports  from  secondary  research  will not be kept in the subje cts’ health  records  or shared  with 
subjects, unless required by [CONTACT_2371]. Reports will not be sent to the specimen repository.  
The subject’s decision can be changed at any time by [CONTACT_122839].  To participate  in this study,  subjects  must  consent  for storage  of samples  for secondary 
use. If the subject subsequently changes his/her decision, the samples will be destroyed if the 
samples have not been used for research or released for a specific research project.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138210], with provision of a methodologically sound proposal, and 
approval from DMID and any approvals required by [CONTACT_122840] n etwork, data may be shared for 
secondary  research  with investigators/researchers.  The data will be available  for only the purpose 
outlined in the approved proposal.  
For access to genomic  data in the NIH designated controlled access database, an investigato r (or 
data requestor) must submit a Data Access Request which certifies adherence to the NIH 
Security Best Practices for Controlled -Access data subject to the NIH Genomic Data Sharing 
(GDS)  Policy.  The participating  site PI [INVESTIGATOR_122765] a research subject withdraws or changes his or her 
consent. However, some data that have been distributed for approved research use cannot be 
retrieved.  
 
Exclusion  of Women,  Minorities,  and Children  (Special  Populations)  
 
 
All healthy adults 18 through 55 years of age, who meet all of the inclusion and none of the 
exclusion criteria (see Section 5.1), regardless o f religion, sex, or ethnic background, will be 
included in the study. Due to the nature of the study, and the fact that no benefit of study 
participation exists, children will not be enrolled at this time. Women who are pregnant or plan 
to become  pregnant  up to [ADDRESS_138211]  injection  and persons  <[ADDRESS_138212] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, 
subject’s clinical information, and all other informati on generated during participation in the 
study.  No information  concerning  the study  or the data generated  from  the study  will be released 
to any unauthorized third party without prior written approval of the DMID and the subject.  
Subject confidentiality wi ll be maintained when study results are published or discussed in 
conferences.  The study monitor or other authorized representatives of the sponsor or 
governmental regulatory agencies may inspect all documents and records required to be 
maintained  by [CONTACT_093],  including  but not limited  to, medical  records  (office,  clinic,  or 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  81  
  
 
 
hospi[INVESTIGATOR_307])  and pharmacy  records  for the subjects  in this study.  The clinical  study  site will permit 
access to such records.  
All records will be kept locked and all computer entry and networking programs will be  carried 
out with coded  numbers only  and with password protected  systems.  All non-clinical  specimens, 
evaluation  forms,  reports,  and other  records  that leave  the site will be identified  only by a coded 
number.  
 
Certificate  of Confidentiality  
As this research is funded by [CONTACT_18121], it is covered by [CONTACT_122841] a Certificate of Confidentiality (COC). By [CONTACT_122842], researchers cannot be forced to 
disclose or provide, in any Federal, State, or local civil, cri minal, administrative, legislative, or 
other proceeding, the name [CONTACT_122867], document, or 
biospecimen that contains identifiable, sensitive information about the individual and that was 
created  or compi[INVESTIGATOR_122766],  unless  such disclosure  or use is made  with the 
consent of the individual to whom the information, document, or biospecimen pertains.  
The Certificate  cannot  be used to resist  a demand  for information  from  personnel  of the United 
States  Government  that is used for auditing  or evaluation  of federally  funded  projects,  like this 
study, or for information that must be released in order to meet the requirements of the FDA.  
A Certificate of Confidentiality does not prevent the sub ject from voluntarily releasing 
information about themselves or their involvement in this research.  If any person or agency 
obtains  a written  consent  to receive  research  information,  then the researchers  may not use the 
Certificate to withhold that informa tion. 
The Certificate of Confidentiality does not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research 
project  regarding  matters  that must  be legally  reported  including:  child  and elder  abuse,  sexual 
abuse, or wanting to harm themselves or others.  
The release  of individual  private  information  or specimens  for other  research  will only occur  if 
consent  was obtained  from  the individual  to whom  the information,  document,  or biospecimen 
pertains, or for the purposes of other research that is in compliance with applicable Federal 
regulations governing the protection of human subjects in research.  
 
Costs,  Subject  Compensation,  and Research  Related  Injuries 
There  is no cost to subjects  for the research  tests,  procedures,  and study  product  while  taking  part 
in this trial.  Procedures and treatment for clinical care may be billed to the subject, subject’s  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138213] party.  Subjects may be compensated for their participation in this trial.  
Compensation  will be in accordance  with the local  IRB’s  policies  and procedures,  and subject  to 
IRB approval.  
If it is determined by [CONTACT_122843] [INVESTIGATOR_122767] a  subject as a  direct 
result  of the tests or treatments  that are done  for this trial, then referrals  to appropriate  health  care 
facilities will be provided to the subject.  Study personnel will try to reduce, control, and treat 
any complications from this trial.  Immediate medical treatment may be prov ided by [CONTACT_122844].  No financial compensation will be provided to the subject by [CONTACT_122845], NIH 
to the subject, for any injury suffered due to participation in this trial.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138214].  If an AE has a 20% chance of occurring after receiving one of the produc t 
formulations being tested, then there is an 87% probability that the event would be observed in 
one or more  of the 9 subjects  in that treatment group  in this study.  If the event  has a 20% chance 
or higher of occurring in any of the product formulations being tested, then there is at >99% 
probability that the event would be observed in one or more of the [ADDRESS_138215]  Probability of 
observing event 
among  9 subjects  Probability of 
observing event 
among  45 subjects  
0.01 0.086  0.364  
0.05 0.370  0.901  
0.10 0.613  0.991  
0.15 0.768  0.999  
0.20 0.866  >0.99  
0.25 0.925  >0.99  
 
Treatment  Assignment  Procedures  
10.3.1  Randomization  Procedures  
This is a non -randomized trial. Per ICH guideline E6: GCP, screening records will be kept at 
each participating  VTEU  site to document  the reason  why an individual  was screened,  but failed 
trial entry criteria. The reasons why individuals failed screening w ill be recorded in the 
Statistical Data Coordinating Center’s (SDCC) Advantage eClinical Electronic Data Capture 
System.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138216] injections; the same 
study product formulation  will be given to the subject for each study product injection.  In the 
unlikely event that a subject withdraws prior to receiving the first injection, the subject will be 
replaced with a new subject who will be given the same treatment assignment.  
10.3.[ADDRESS_138217]  ID number  and sample 
visit number.  
The SMC may  receive  data in aggregate  and presented  by [CONTACT_122846].  
 
Planned  Interim  Analyses  
Interim analyses will be used to terminate this trial in the event that unanticipated safety events 
deemed to be of sufficient concern require such action by [CONTACT_456]. These assessments will 
not be made  on the basis  of testing  a formal  statistical  hypot hesis;  therefore,  p-value  adjustment 
will not be made to any analyses. A SMC will be convened by [CONTACT_122847],  clinical,  safety,  reactogenicity  and immunogenicity  data as described  in Section 
8.7 
To guide protocol development of future studies of the candidate vaccine, interim analyses of 
safety  data and immunogenicity  assays,  including  the IgG ELISA  assay,  will be performed at  the 
discretion of the study team prior to completion of follow -up of all subjects. The interim 
immunogenicity analyses report(s) will include between -Group comparisons of those who 
received different Sm -p80 study product formulations and different schedule s. The information 
from the report may be used in abstracts and scientific presentations and reports.  
10.4.1  Interim  Safety  Review  
An interim  safety  review  may include  enrollment  and demographic  information,  medical  history, 
concomitant  medications,  physical  assessments,  dosing  compliance,  and solicited  and unsolicited 
AE/SAEs. Additional data may be requested by [CONTACT_4484], and interim statistical reports may be 
generated as deemed necessary and appropriate by [CONTACT_122830]. The SMC may receive data in 
aggregate  and presented  by [CONTACT_2890]. The SMC  will meet  and review  this data at scheduled 
time points  or ad hoc as needed  during  this trial as defined  in the SMC  charter.  As an outcome  of 
each review/meeting, the SMC will make a recommendation as to the advisability of proceeding  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  85  
  
 
 
with study  vaccinations  (as applicable),  and to continue,  modify,  or terminate  this trial. 
Additionally,  this trial will be monitored  to determine  if any of the halting  rules  described  in 
Section 8.6 are met.  
10.4.2  Interim  Immunogenicity  or Efficacy  Review  
Interim i mmunogenicity analyses of, for example, IgG ELISA responses will be performed for 
each Study  Group, as  the data is available  for each study  group.  Depending on  the timing  of data 
availability, a report may cover one or more Study Groups. Immunogenicity reports will be 
provided by [CONTACT_122848], the IDCRC LOU 
representative(s), the study PI [INVESTIGATOR_122768], and the SMC. Reports will include data  
summarized by [CONTACT_122849]. The data will be cleaned but not locked. These reports along with 
interim  safety  results  may be presented  in publications,  or public  forums  and used by [CONTACT_122850] -making.  
 
Final  Analysis  Plan  
Analyses  for this Phase  [ADDRESS_138218] all planned measurements.  Statistical 
adjustments for missing data are not planned, but sensitivity analyses may be performed if 
warranted.  
An interim CSR will be completed when all primary and secondary endpoint data are available, 
received by [CONTACT_80938], cleaned, and locked. Exploratory endpoint data will be included in an 
addendum  to the CSR  once  available,  received  by [CONTACT_80938],  cleaned,  and locked.  Endpoint  data 
may be included in publication of manuscript(s) or other reports.  
Separate  SAP documents  (interim  and addendum)  will be generated  that will contain  the details 
of the final analyses that will be performed following database lock. This  section outlines the 
major components of the final analyses.  
10.5.[ADDRESS_138219] 
deviation; categorical variables will be tabulated.  
10.5.[ADDRESS_138220] one vaccination will be included in safety summaries. 
Solicited  and unsolicited  events will be summarized  graphically  and numerically.  Numbers  and 
proportions of participants experiencing solicited systemic events will be summarized by  

[CONTACT_122851]  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138221]-study vaccination  blood  sample  for 
immunogenicity testing for which valid results were reported. Antibody levels will be 
summarized graphically and numerically.  Individual time trends will be visualized as will 
reverse cumulative distribution plots.  Numbers and proportions of participants with 
seroconversion,  defined  as a fourfold  rise from  baseline,  will be presented  along  with 95% CIs 
by [CONTACT_122852].  Statistical  summaries  will include  geometric  means,  geometric 
mean  fold-rise, mean,  median,  standard  deviation,  minimum,  and maximum by  [CONTACT_122853].  
10.5.[ADDRESS_138222] human reference genome using 
splice -aware alignment software such as HISAT2.[25] Gene expression quantification will be 
carried out by [CONTACT_122854] [26]using the latest Ensembl[27]gene model 
annotations as a reference. Systematic  differences in sequence coverage between samples will be 
accounted  for using  the TMM  method [31]as  implemented  in the edgeR  R package.[28]  Principal 
component analysis, non -metric multidim ensional scaling, and hierarchical clustering analysis 
will be used to identify potential global outliers and systematic batch effect. Negative binomial 
models  as implemented  in edgeR  [28]will  be used to identify  genes  for each dose group  and post- 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138223] vaccination:  Days 8 and 29 
vs. Day 1, and Day 36 vs. Day 29 for all study  groups,  Day 57 vs. Day 29, Day  64 vs. Day 57 for 
Groups A, B, D, and E, Day 187 vs. Day 180 for Group C. To control for testing multiple genes, 
the false -discovery rate based on the Benjamini -Hochberg procedure[32] as implemented in the 
p.adjust R function will be applied. The pvclust [33]R package will be used to identify co - 
expressed DE gene clusters. Mean cluster log 2 fold change time trends and associated 95% 
bootstrap confidence intervals (CIs) will be presented by [CONTACT_122855] -vaccinat ion days. To 
functionally characterize differently expressed genes, pathway enrichment analysis based on the 
latest MSigDB [34]and KEGG databases[35] as well as Blood Transcription Modules will be 
carried out using the implementation provided by [CONTACT_122856] R package [36]which accounts for 
RNA -Seq gene length bias. Pathway maps color -coded by [CONTACT_122857] (log 2 fold change 
compared to pre -vaccination) will be visualized for significantly enriched KEGG pathways.  
Pathway enrichment trends by [CONTACT_122858]-vaccination days will be visualized using 
bubble plots contrasting median pathway response with pathway enrichment as well as time 
trend plots of median pathway responses (based on median average log [ADDRESS_138224] members) and associated 95% bootstrap CIs. Regularized linear and/or logistic 
regression  analysis  as implemented  in the glmnet  R package  [37]will  be utilized  to identify  gene 
expression  changes  that are predictive  of antibody  levels  that provide  protective  efficacy ex vivo 
as mea sured using passive transfer. Cross -validation in combination with bootstrap resampling 
will be used to select optimal models and to assess robustness of variable selections. Please see 
the separate document “Statistical Analysis Plan” for additional infor mation on exploratory 
RNA -Seq analyses.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  88  
  
 
 
 
SOURCE  DOCUMENTS  AND  ACCESS  TO SOURCE 
DATA/DOCUMENTS  
 
Each participating site will maintain appropriate medical and research records in compliance  
with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of 
confidentiality of subjects. Each site will permit authorized representatives of the DMID, its 
designees,  and appropriate  regulatory  agencies  to examine  (and when  required  by [CONTACT_61285], 
to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of 
the study safety and progress. These representatives will be permitted access to all source data 
and source documents, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office 
charts, laboratory notes, memoranda, subjects’ memory aid or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_122769],  microfiches,  photographic  negatives,  microfilm 
or magnetic  media,  x-rays,  and subject  files and records  kept at the  pharmacy,  at the laboratories, 
and medico -technical departments involved in the clinical trial.  
This study  uses direct  data entry  for the participating  clinic site and the eCRFs  serve  as the 
source documents for data collected.  
Subjects will use a web -based electronic Memory Aid (e -Memory aid), or paper Memory Aid if 
internet  access  is not available.  Data  entered  by [CONTACT_122859] e-Memory  Aid are stored  in the 
data system  for clinic  staff review  during  scheduled  visits.  The e-Memory  Aid is not considered 
source data. After clinic staff review and save the data, the data will be entered into Advantage 
eClinical as source.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  89  
  
 
 
 
QUALITY  CONTROL  AND QUALITY  ASSURANCE  
 
Following a written DMID -accepted site quality management plan, each participating site(s) and 
its subcontractors are responsible for conducting routine quality assurance and quality control 
activities to internally monitor study progress and protocol compliance.  The site principal 
investigator  [INVESTIGATOR_122770] -related  sites,  source  data/data  collection  forms, 
and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_12291].  The site principal investigator [INVESTIGATOR_122771].  
The SDCC  will implement  quality  control  procedures  beginning  with the data entry  system  and 
generate data quality control checks that will be run on the database.  Any missing data or  data 
anomalies will be communicated to the participating site(s) for clarification and resolution.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138225]  KEEPI[INVESTIGATOR_122772],  completeness,  and timeliness 
of the data reported.  
 
Data will be entered electronically over the Internet by [CONTACT_122860], 
developed and m aintained by [CONTACT_80938]. The eCRFs serve as the source documents for data 
collected.  Paper case report forms derived from the eCRF are provided by [CONTACT_122861]. Details on data handling procedures, 
procedures  for data monitoring,  and instructions  for use of the system  and completion  of the eCRFs 
are provided in the study MOP, eCRF Instructions, and Advantage eClinical User’s Guide.  
 
The sponsor  and/or  its designee  will provide  guidance  to the site principal  investigators  and other 
study personnel on making corrections to the eCRF.  
 
Data  Coordinating  Center/Biostatistician  Responsibilities  
Data  collection  is the responsibility  of the study  personnel  at the participating  clinical  study  site 
under the supervision of the site principal investigator.  During the study, the site principal 
investigator [INVESTIGATOR_122773].  
Emmes  will serve  as the SDCC  for this study,  and will be responsible  for data management, 
quality review, analysis, and reporting of the study data.  
 
Data  Capture  Methods  
Clinical (including, but not limited to, AE/SAEs, concomitant medications, medical history, 
physical assessments, and clinical laboratory val ues) and reactogenicity will be entered into 
eCRFs  via a [ADDRESS_138226] of all authorized  data originators,  including 
site staff, will be included on the Study Personnel/Signature [CONTACT_122868].  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  91  
  
 
 
 
Types  of Data  
Data  for this trial will include  clinical,  safety,  and outcome  measures  (e.g.,  clinical  laboratory 
values, reactogenicity, and immunogenicity data).  
 
Study  Records  Retention  
Study records and reports including, but not limited to, eCRFs, source documents, ICFs, 
laboratory test results, and study drug disposition records will be retained for two years after a 
marketing application is approved for the study product for the indic ation for which it is being 
investigated;  or, if no application  is to be filed or if the application  is not approved  for the study 
product, until two years after the investigation is discontinued and the FDA has been notified. 
These  documents  will be retai ned for a longer  period,  however,  if required by  [CONTACT_56819]. 
ICFs for future use will be maintained as long as the sample/specimen exists.  
No records  will be destroyed  without  the written  consent  of the sponsor.  It is the responsibility  of 
the sponsor to inform the site principal investigator [INVESTIGATOR_122774]. The participating VTEU sites must contact [CONTACT_122862].  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  92  
  
 
 
 
CLINICAL  MONITORING  
 
Site monitoring  is conducted  to ensure  that the human  subjects’  protections,  study  and laboratory 
procedures, study intervention administration, and data collection proces ses are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is 
conducted in accordance with the protocol, protocol -specific MOP and applicable sponsor 
standard operating procedures.  DMID, the sponsoring agen cy, or its designee will conduct site - 
monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by [CONTACT_122863].  Monitoring  visits  will include,  but are not limited  to, review  of 
regulatory files, accountability records, eCRFs, ICFs, medical and labo ratory reports, and 
protocol and GCP compliance.  Site monitors will have access to each participating site, study 
personnel, and all study documentation according to the DMID -approved site monitoring plan. 
Study  monitors  will meet  with site principal  inves tigators  to discuss  any problems  and actions  to 
be taken and will document site visit findings and discussions.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138227] submitted for 
them  to the National  Library  of Medicine’s  PubMed  Central  (http://www.n cbi.nlm.nih.gov/pmc/)  
an electronic version of their final, peer -reviewed manuscripts upon acceptance for publication, 
to be made publicly available no later than [ADDRESS_138228] be accessible to the public on PubMed Central no 
later than 12 months after publication.  
Refer  to: 
• NIH Public  Access  Policy,  http://publicaccess.nih.gov/  
• NIH Office  of Extramural  Research  (OER)  Grants  and Funding, 
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical t rials supported by [CONTACT_12242].gov, no later than [ADDRESS_138229] applied for certification of delayed posting.  
As part of the result  posting  a copy  of this protocol  (and its amendments)  and a copy  of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the responsible  party  is DMID  which  will register  the trial and post results. 
The responsible party does not plan to request certification of delayed posting.  
Refer  to: 
• Public Law 110-85, Section  801, Clinical  Trial  Databases  
• 42CFR11  
• NIH NOT -OD-16-149 

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  94  
  
 
 
 
LITERATURE  REFERENCES  
 
1. Gryseels  B, Polman  K, Clerinx  J, Kestens  L. Human  schistosomiasis.  Lancet . Sep 23 
2006;368(9541):1106 -18. doi:10.1016/S0140 -6736(06)[ZIP_CODE] -3 
2. Savioli  L, Mott  KE. Urinary  schistosomiasis  on Pemba  Island:  low-cost diagnosis  for 
control in a primary health care setting. Parasitol Today . Oct 1989;5(10):333 -7. 
3. De Vlas SJ, Engels D, Rabello AL, et al. Validation of a chart to estimate true 
Schistosoma  mansoni  prevalences  from  simple  egg counts.  Parasitology . Feb 1997;114  ( Pt 
2):113 -21. 
4. King  CH. Parasites  and poverty:  the case of schistosomiasis.  Acta Trop . Feb 
2010;113(2):95 -104. doi:10.1016/j.actatropi[INVESTIGATOR_19529].2009.11.012  
5. Hotez  PJ, Strych  U, Lustigman  S, Bottazzi  ME. Human  anthelminthic  vaccines: 
Rationale and challenges. Vaccine . Jun 24 2016;34(30):3549 -55. 
doi:10.1016/j.vaccine.2016.03.112  
6. Mo AX, Colley  DG. Workshop  report:  Schistosomiasis  vaccine  clinical  development  and 
product characteristics. Vaccine . Feb 17 2016;34(8):995 -1001.  
doi:10.1016/j.vaccine.2015.12.[ADDRESS_138230] of a partially efficacious vaccine 
on the transmission  dynamics  of Schistosoma  mansoni  in human  communities. Parasit  Vectors . 
Jun 17 2017;10(1):294. doi:10.1186/s13071 -017-[ADDRESS_138231]  Dis. Nov 2011;204(9):1437 -49. doi:10.1093/infdis/jir545  
9. Zhang  W, Molehin  AJ, Rojo  JU, et al. Sm-p80-based  schistosomiasis  vaccine:  double - 
blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite 
transmission -blocking efficacy.  Ann N Y Acad Sci . Aug 2018;1425(1):38 -51. 
doi:10.1111/nyas.[ZIP_CODE]  
10. Siddiqui  AJ, Molehin  AJ, Zhang  W, et al. Sm-p80-based  vaccine  trial in baboons: 
efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, 
immunization, and Schistosoma mansoni re -encounter. Ann N Y Acad Sci . Jun 11 
2018;doi:10.1111/nyas.[ADDRESS_138232]  Dis. Jun 15 
2014;209(12):1929 -40. doi:10.1093/infdis/jiu031  
12. Karmakar S, Zhang W, Ahmad G, et al. Cross -species protection: Schistosoma  mansoni 
Sm-p80 vaccine  confers  protection  against  Schistosoma  haematobium  in hamsters  and baboons. 
Vaccine . Mar 5 2014;32(11):1296 -303. doi:10.1016/j.vaccine.2013.12.057  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  95  
  
 
 
13. Molehin AJ, Sennoune SR, Zhang W, et al. Cross -species prophylactic efficacy of Sm - 
p80-based vaccine and intracellular localization of Sm -p80/Sm -p80 ortholog proteins during 
development  in Schistosoma  mansoni,  Schistosoma  japonicum,  and Schistosoma  haemat obium. 
Parasitol Res . Nov 2017;116(11):3175 -3188. doi:10.1007/s00436 -017-5634 -4 
14. Zhang W, Ahmad G, Le L, et al. Longevity of Sm -p80-specific antibody responses 
following  vaccination  with Sm-p80 vaccine  in mice  and baboons  and transplacental  transfer  of 
Sm-p80-specific antibodies in a baboon. Parasitol Res . Jun 2014;113(6):2239 -50. 
doi:10.1007/s00436 -014-3879 -8 
15. Coler  RN, Duthie  MS, Hofmeyer KA, et al. From mouse  to man: safety, immunogenicity 
and efficacy  of a candidate  leishmaniasis  vaccine  LEISH -F3+GLA -SE. Clin Transl  Immunology . 
Apr 2015;4(4):e35. doi:10.1038/cti.2015.[ADDRESS_138233] adjuvant, GLA -SE, improves 
magnitude  and quality  of immune  responses  elicited  by [CONTACT_122864]93  tuberculosis  vaccine:  first-in- 
human trial. NPJ Vaccines . 2018;3:34. doi:10.1038/s41541 -018-0057 -5 
17. Penn -Nicholson  A, Tameris  M, Smit  E, et al. Safety  and immunogenicity  of the novel 
tuberculosis vaccine ID93 + GLA -SE in BCG -vaccinated healthy adults in South Africa: a 
randomised, double -blind, placebo -controlled phase 1 trial. Lancet Respir Med . Apr 
2018;6(4):287 -298. doi:10.1016/S2213 -2600(18)[ADDRESS_138234] ed by [CONTACT_122865] -SE 
adjuvants  in a Phase  2 clinical  trial. NPJ Vaccines . 2018;3:3.  doi:10.1038/s41541 -017-0043 -3 
19. Treanor JJ, Essink B, Hull S, et al. Evaluation of safety and immunogenicity of 
recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a 
stable  oil-in-water  emulsion  containing  glucopyranosyl -lipid A (SE+GLA)  adjuvant.  Vacci ne. 
Nov 19 2013;31(48):5760 -5. doi:10.1016/j.vaccine.2013.08.064  
20. Santini -Oliveira M, Coler RN, Parra J, et al. Schistosomiasis vaccine candidate 
Sm14/GLA -SE: Phase  1 safety  and immunogenicity  clinical  trial in healthy,  male  adults. 
Vaccine . Jan 20 2016;34( 4):586 -594. doi:10.1016/j.vaccine.2015.10.027  
21. Sirima SB, Durier C, Kara L, et al. Safety and immunogenicity of a recombinant 
Plasmodium falciparum AMA1 -DiCo malaria vaccine adjuvanted with GLA -SE or 
Alhydrogel(R)  in European  and African  adults:  A phase  1a/1b,  randomized,  double -blind  multi - 
centre trial. Vaccine . Oct 27 2017;35(45):6218 -6227. doi:10.1016/j.vaccine.2017.09.027  
22. Belshe  RB, Frey SE, Graham  I, et al. Safety  and immunogenicity  of influenza  A H5 
subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis . Mar 1 
2011;203(5):666 -73. doi:10.1093/infdis/jiq093  
23. Marsano  LS, Greenberg  RN, Kirkpatrick  RB, et al. Comparison  of a rapid  hepatitis  B 
immunization schedule to the standard schedule for adults. Am J Gastroenterol . Jan 
1996;91(1):[ADDRESS_138235] Dis . Dec 01 2016;214(11):1717 -1727. doi:10.1093/infdis/jiw414  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  96  
  
 
 
25. Kim D, Langmead  B, Salzberg  SL. HISAT:  a fast spliced  aligner  with low memory 
requirements. Nat Methods . Apr 2015;12 (4):357 -60. doi:10.1038/nmeth.3317  
26. Liao Y, Smyth  GK, Shi W. featureCounts:  an efficient  general  purpose  program  for 
assigning sequence reads to genomic features. Bioinformatics . Apr 1 2014;30(7):923 -30. 
doi:10.1093/bioinformatics/btt656  
27. Aken  BL, Achuthan  P, Akanni  W, et al. Ensembl  2017.  Nucleic  Acids  Res. Jan 4 
2017;45(D1):D635 -D642. doi:10.1093/nar/gkw1104  
28. Robinson  MD, McCarthy  DJ, Smyth  GK. edgeR:  a Bioconductor  package  for differential 
expression analysis of digital gene expression data. Bioinformatics . Jan 1 2010;26(1):139 -40. 
doi:10.1093/bioinformatics/btp616  
29. Siddiqui  AA, Pi[INVESTIGATOR_122775], Quinlin  ML, et al. Characterization  of the immune  response  to 
DNA vaccination strategies for schistosomiasis candidate antigen, Sm -p80 in the baboon. 
Vaccine . Feb 10 2005;23(12):1451 -6. doi:10.1016/j.vaccine.2004.09.018  
30. Torben W, Ahmad G, Zhang W, et al. Role of antibody dependent cell mediated 
cytotoxicity  (ADCC)  in Sm-p80-mediated  protection  against  Schistosoma  mansoni.  Vaccine . 
Nov 6 2012;30(48):6753 -8. doi:10.1016/j.vaccine.2012.09.026  
31. Robinson  MD, Oshlack  A. A scaling  normalization  method  for differential  expression 
analysis of RNA -seq data. Genome Biol . 2010; 11(3):R25. doi:10.1186/gb -2010 -11-3-r25 
32. Benjamini  Y, Hochberg  Y. Controlling  the false  discovery  rate: a practical  and powerful 
approach to multiple testing. Journal of the royal statistical society Series B (Methodological) . 
1995:[ADDRESS_138236]:  an R package  for assessing  the uncertainty  in 
hierarchical clustering. Bioinformatics . Jun 15 2006;22(12):1540 -2. 
doi:10.1093/bioinformatics/ btl117  
34. Liberzon  A, Subramanian  A, Pi[INVESTIGATOR_122776]  R, Thorvaldsdottir  H, Tamayo  P, Mesirov  JP. 
Molecular signatures database (MSigDB) 3.0. Bioinformatics . Jun 15 2011;27(12):1739 -40. 
doi:10.1093/bioinformatics/btr260  
35. Kanehisa  M, Goto  S. KEGG:  kyoto  encyclopedia  of genes  and genomes.  Nucleic  Acids 
Res. Jan 1 2000;28(1):27 -30. doi:10.1093/nar/28.1.27  
36. Young  MD, Wakefield  MJ, Smyth  GK, Oshlack  A. Gene  ontology  analysis  for RNA -seq: 
accounting for selection bias. Genome Biol . 2010;11(2):R14. doi:10.1186/gb -2010 -11-2-r14 
37. Friedman  J, Hastie  T, Tibshirani  R. Regularization  Paths  for Generalized  Linear  Models 
via Coordinate Descent. J Stat Softw . 2010;33(1):1 -22. 
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  97  
  
 
 
 
APPENDICES  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  98  
  
 
 
 Schedules of Events  
Table  7: Screening  Visit  Evaluations  and Procedures.  
 
  Screen  
Study  day  -[ADDRESS_138237]  demographic  information   X 
Complete  physical  exam  and height  and weight,  calculate  BMI  X 
Vital  signs  (blood  pressure,  pulse,  and oral temperature)   X 
Provide  HIV test counseling   X 
Review  of contraceptive/menstrual  history;  pregnancy  avoidance  counseling1  X 
Pregnancy  test (serum)1, creatinine,  ALT,  HIV-1/HIV -2 testing,  anti-HCV  antibody,  HBsAg 
(mL)  SST 25.5 
WBC,  hemoglobin,  platelets  (mL)  EDTA  4 
Blood  Volume  (mL)   29.5 
 
1For women  of childbearing  potential.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  99  
  
 
 
 
Table  8: Schedule  of Events  and Study  Procedures,  Study  Groups  A, B, D, and E 
 
 
  Study  Product  Injection  and Follow  Up Visits  
Study  day  [ADDRESS_138238]  recent  
vaccination   0 1 3 7 28 3 7 28 3 7 28 124 365 
Visit  Window  (± 
number  of days)   0 0 1 1 3 1 1 3 1 1 3 14 14 
Study  visit  01 02P 03 04 05 06 07 08 09 10 11 12 13P 
Clinical  Evaluations  
and Procedures  Tube               
Assessment  of 
eligibility   X             
Assessment  of 
individual  halting  
criteria        
X    
X      
Review  medical  
history  and con meds3  X X X X X X X X X X X X X 
Vital signs (blood  
pressure,  pulse,  and 
oral temperature5)   
X   
X  
X  
X  
X  
X  
X  
X  
X  
X4  
X4  
Enrollment   X             
Study  Product  
Injection1  I-1    I-2   I-3      
Targeted  physical  
exam   {X}  {X} {X} {X} {X} {X} {X} {X} {X} {X} {X}  
Pre-administration  
reactogenicity  
assessment    
X     
X    
X      
Evaluate study  
product  injection  site  X  X X X X X X X X    
Provide and explain  
use of memory  aid and 
thermometer    
X     
X    
X      
Review  memory  aid   X X X  X X  X X    
Collection  of solicited  
AEs  X X X X X X X X X X    
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138239]  recent  
vaccination   0 1 3 7 28 3 7 28 3 7 28 124 365 
Visit  Window  (± 
number  of days)   [ADDRESS_138240] (urine)2  X    X   X      
WBC,  hemoglobin,  
platelets (mL)  EDTA  [ADDRESS_138241] 10   10 10  10 10  10 10   
Serum  collection  for 
antibody assays  and 
secondary research  
(mL)   
SST  
8.5    
8.5  
8.5   
8.5  
8.5   
8.5  
8.5  
8.5  
PBMC  isolation  for 
secondary research  
(mL)   
NaHep/  
ACD7  
60    
60  
60   
60  
60   
60  
34  
60  
Whole  blood  
collection  for gene  
expression  assays  PAXGe  
ne  
2.5    
2.5  
2.5   
2.5  
2.5   
2.5    
Total  volume  per visit 
(mL)   84    
84  
84   
84  
84   
84  
55.5  
68.5  
Cumulative  volume  
(prior 56 days)   113. 
5   197. 
5 281. 
5  365. 
5 420  420 391. 
5 68.5  
{ } required  at this visit only if clinically  indicated  
P=phone  assessment  
10.[ADDRESS_138242] injection and contin uing daily for the  next 
seven days. Subjects will be  encouraged to take  their temperature  around the same  time each day and also if they feel feverish. Subjects  
will be instructed on how to use the memory aid and how to rate any AEs. Subjects will also be instructed to notify the study center if  
they develop any severe reactions and/or fever ≥ 38°C (100.4°F).  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138243]. The  visit will also include  review  of 
contraceptive/menstrual history and pregnancy avoidance counseling.  
 
3After  Study  Visit  11 (or  Study Day  85 if Study Visit  11 is not attended),  through  the end of study follow -up (Day  422),  only SAEs,  MAAEs,  
NOCMCs, and PI[INVESTIGATOR_122777]. Other unsolicited AEs and concomitant medications will not be collected.  
4Vital  signs  will be assessed  only if clinically  indicated.  
 
5Subjects  must  not eat or drink  anything  hot or cold,  or smoke  within  [ADDRESS_138244]  blood  that will be processed  for PBMC  if appropriate  NaHep  tubes  are unavailable.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  102  
 Table  9: Schedule  of Events  and Study  Procedures,  Study  Group  C. 
 
Study  day  [ADDRESS_138245]  recent  vaccination   0 1 3 7 28 3 7 28 151 3 7 28 124 365 
Visit  Window  (± number  of days)   0 0 1 1 3 1 1 3 7 1 1 3 14 14 
Study  visit  01 02P 03 04 05 06 07 08 09 10 11 12 13 14P 
Clinical  Evaluations  and Procedures  Tube                
Assessment  of eligibility   X              
Assessment  of individual  halting  criteria       X    X      
Review  medical  history  and con meds3  X X X X X X X X X X X X X X 
Vital  signs  (blood  pressure,  pulse,  and oral 
temperature5)  X  X X X X X X X X X X4 X4  
Enrollment   X              
Study  Product  Injection1  I-1    I-2    I-3      
Targeted  physical  exam   {X}  {X} {X} {X} {X} {X} {X} {X} {X} {X} {X} {X}  
Pre-administration  reactogenicity  assessment   X    X    X      
Evaluate  study  product  injection  site  X  X X X X X  X X X    
Provide  and explain  use of memory  aid and 
thermometer   X    X    X      
Review  memory  aid   X X X  X X   X X    
Collection  of solicited  AEs  X X X X X X X  X X X    
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138246]  recent  vaccination   0 1 3 7 28 3 7 28 151 3 7 28 124 365 
Visit  Window  (± number  of days)   [ADDRESS_138247] (urine)2  X    X    X      
WBC,  hemoglobin,  platelets  (mL)  EDTA  [ADDRESS_138248] 10   10 10  10 10 10  10 10   
Serum  collection  for antibody  assays  and secondary  
research (mL)  SST 8.5   8.5 8.5  8.5 8.5 8.5  8.5 8.5 8.5  
PBMC  isolation  for secondary  research  (mL)  NaHep/ACD7 60   60 60  60 60 60  60 34 60  
Whole  blood  collection  for gene  expression  assays  PAXGene  2.5   2.5 2.5  2.5  2.5  2.5    
Total  volume  per visit (mL)   84   84 84  84 84 84  84 55.5 68.5  
Cumulative  volume  (prior  56 days)   113.5    197.5  281.5   365.5  420 84  168 223.5  68.5  
 
 
{ } required  at this visit only if clinically  indicated  
P=phone  assessment  
10.[ADDRESS_138249] leaves the clinic. Subjects will be  
provided with a Memory Aid and thermometer for recording daily maximum oral temperature, solicited injection site and systemic reactions, unsolicited AEs, and concomitant medications,  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138250]  injection  and continuing  daily  for the next seven  days.  Subje cts will be encouraged  to take their temperature  around  the same time  each day 
and also if  they feel feverish. Subjects will be instructed on how to use the  memory aid and how  to rate any AEs. Subjects will also be instructed to notify the study center  if they develop any  
severe reactions and/or fever ≥ 38°C (100.4°F).  
2For women  of childbearing  potential. Must  be confirmed  as negative  prior  to injection  of study  product.  The visit will also include  review  of contraceptive/menstrual  history and  pregnancy  avoidance  
counseling.  
 
3After Study Visit 8 (or Study Day 57 if Study Visit 8 is  not attended), through the time  of the  third study vaccination at Study Visit 09, only SAEs, MAAEs, NOCMCs, and PI[INVESTIGATOR_122778].  
Other  unsolicited AEs  and concomitant  medications  will not be collected during  this period. Collection  of unsolicited  AEs and  concomitant medications will  then resume at  the time of the third  
vaccination and continue through Study Visit 12 (or  Study Day 208 if Study Visit 12 is not attended), after which only SAEs, MAAEs, NOCMCs, and PI[INVESTIGATOR_122777].  
4Vital  signs  will be assessed  only if clinically  indicated.  
 
5Subjects  must  not eat or drink  anything  hot or cold,  or smoke  within  [ADDRESS_138251]  blood  that will be processed  for PBMC  if appropriate  NaHep  tubes  are unavailable.  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  [ADDRESS_138252] of Potentially  Immune -Mediated  Medical  Conditions 
(PI[INVESTIGATOR_106279])  
Gastrointestinal  disorders  
 
• Celiac  disease  (gluten -sensitive  enteropathy)  
• Inflammatory  bowel  disease  (Crohn’s  disease,  ulcerative  colitis or  proctitis)  
 
Liver  disorders  
 
• Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary  biliary  cirrhosis  
• Primary  sclerosing  cholangitis  
 
Metabolic  diseases  
 
• Primary  adrenal  insufficiency  (Addison’s  disease)  
• Chronic  lymphocytic  thyroiditis  (Hashimoto’s  disease)  (Not exclusionary  for enrollment)  
• Diabetes  mellitus  type I 
• Graves’  or Basedow’s  disease  
 
Musculoskeletal  disorders  
 
• Antisynthetase  syndrome  
• Dermatomyositis  
• Juvenile  chronic  arthritis/juvenile  idiopathic  arthritis  (including  juvenile  Still’s  disease 
[macrophage activating syndrome])  
• Mixed  connective  tissue  disorder  
• Polymyalgia  rheumatica  
• Polymyositis  
• Psoriatic  arthritis  
• Relapsing  polychondritis  
• Rheumatoid  arthritis  
• Scleroderma,  including  diffuse  systemic  form  and CREST  syndrome  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  106  
  
 
 
• Spondyloarthritis,  including  ankylosing  spondylitis,  reactive  arthritis  (Reiter's  Syndrome) 
and undifferentiated spondyloarthritis  
• Systemic  lupus  erythematosus  
• Systemic  sclerosis  
 
Neuroinflammatory  disorders  
 
• Acute  disseminated  encephalomyelitis,  including  site specific  variants  (e.g.,  non- 
infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis)  
• Possibly  immune -mediated  cranial  nerve  disorders  (e.g.,  Bell’s  palsy)  
• Guillain -Barré  syndrome,  including  Miller  Fisher  syndrome  and other  variants  
• Immune -mediated  peripheral  neuropathies  and plexopathies,  including  chronic 
inflammatory  demyelinating  polyneuropathy,  multifocal  motor  neuropathy  and 
polyneuropathies associated with monoclonal  gammopathy  
• Multiple  sclerosis  
• Optic  neuritis  
• Transverse  myelitis  
• Myasthenia  gravis,  including  Lambert -Eaton  myasthenic  syndrome  (LEMS)  
 
Skin  disorders  
 
• Alopecia  areata  
• Autoimmune  bullous  skin diseases,  including  pemphigus,  pemphigoid  and dermatitis 
herpetiformis  
• Cutaneous  lupus  erythematosus  
• Erythema  nodosum  
• Localized  scleroderma  (morphea)  
• Lichen  planus  
• Psoriasis  (May  not be exclusionary  for enrollment,  see Section  5.1.2 ) 
• Acute  febrile  neutrophilic  dermatosis  (Sweet’s  syndrome)  
• Vitiligo  (May  not be exclusionary  for enrollment,  see Section  5.1.2 ) 
 
Vasculitides  
 
• Large  artery  vasculitis:  Takayasu’s  arteritis  and giant  cell arteritis  (temporal  arteritis)  
• Small  and medium -sized  artery  vasculitis:  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  107  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Others  o Polyarteritis  nodosa  
o Mucocutaneous  lymph  node  syndrome  (Kawasaki  disease)  
o Microscopic  polyangiitis  
o Granulomatosis  with polyangiitis  (Wegener's  granulomatosis)  
o Eosinophilic  granulomatosis  with polyangiitis  (Churg -Strauss  syndrome)  
o Thromboangiitis  obliterans  (Buerger’s  disease)  
o Necrotizing  vasculitis  (systemic  necrotizing  vasculitis)  
o Antineutrophil  cytoplasmic  antibody  (ANCA) -associated  vasculitis  
o IgA vasculitis  (Henoch -Schonl ein purpura)  
o Behcet's  syndrome  
o Leukocytoclastic  vasculitis  (hypersensitivity  vasculitis)  
 
• Antiphospholipid syndrome  
• Autoimmune  hemolytic  anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapi[INVESTIGATOR_90974],  membranous  glomerulonephritis,  membranoproliferative  glomerulonephritis, 
and mesangioproliferative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia  
• Goodpasture  syndrome  
• Idiopathic  pulmonary  fibrosis  
• Pernicious  anemia  
• Raynaud’s  phenomenon  
• Sarcoidosis  
• Sjögren’s  syndrome  
• Stevens-Johnson  syndrome  
• Uveitis  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  108  
  
 
 
 
Toxicity  Tables  
 
 
Parameters  for solicited  AEs are reported  in Table  3, Table  4, Table  5, and Table  6. 
 
 
Pulse  and Blood  Pressure  
 
Physiologic  Parameter  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
Tachycardia  - beats  per minute  101 - 115 116 - 130 > 130 
Hypotension  (systolic)  mm Hg1 85 – 89 80 – 84 <80 
Hypertension  (systolic)  mm Hg2 141 – 150 151 – 155 > 155 
Hypertension  (diastolic)  mm Hg3 96 – 100 101 – 105 >105  
 
 
The inclusion  criteria  for systolic  blood  pressure  includes  values  from  85 through  150, inclusive 
and for diastolic blood pressure includes values ≤ 100.  
 
1Subjects with baseline (prior to first vaccination) Grade 1 values of 85 -89 mm Hg are defined 
with a hypotension  (systolic)  AE only due to post-vaccination  values  ≤ 84 mm Hg and the AE is 
Defined as Grade 1 based on values of 80 through 84 and Grade 2 based on values less than 80.  
 
2Subjects  with baseline  (prior  to first vaccination)  Grade  1 values  of 141-150 mm Hg are defined 
with a hypertension (systolic) AE only due to post -vaccination v alues over 150 mm Hg and the 
AE is Defined as Grade 1 based on values of 151 through 155 mm Hg and Grade 2 based on 
values over 155.  
 
3Subjects with baseline (prior to first vaccination) Grade 1 values of 96 -100 mm Hg are defined 
with a hypertension  (diastolic)  AE only due to post-vaccination  values  ≥ 101 mm Hg and the AE 
is Defined as Grade 1 based on values of 101 through 105 mm Hg and Grade 2 based on values 
over 105.  

DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  109  
  
 
 
Clinical  Safety  Laboratory  Values  
 
Hematology  Mild 
(Grade  1) Moderate 
(Grade  2) Severe 
(Grade  3) 
WBC  103/UL (Decrease)  2.50 – 3.50 1.50 – 2.49 <1.50  
WBC  103/UL (Increase)  13.01  – 15.00  15.01  – 20.00  >20.00  
HgB  g/dL  (Decrease)  (Female)  11.0 – 11.49  9.5 – 10.9 <9.5 
HgB  g/dL  (Decrease)  (Male)  12.0 – 12.5 10.0 – 11.9 <10.0  
Platelets  103/UL (Decrease)  120 – 130 100 – 119 <100  
Platelets  103/UL (Increase)  416 – 550 551– 750 >750  
    
Chemistry     
ALT  IU/L  (Increase)  47 – 105 106 – 175 >175  
Creatinine  mg/dL  (Increase)  > ULN  – 1.7 1.8 – 2.0 >2.[ADDRESS_138253]  = upper  limit  of normal  range  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  110  
  
Clinical  Adverse  Events  
CARDIOVASCULAR  Mild  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) 
Arrhythmia   asymptomatic,  transient 
signs, no Rx required  recurrent/persistent; 
symptomatic Rx 
required  
Hemorrhage,  Blood  Loss Estimated 
blood  loss < 
100 mL  Estimated blood loss > 
100 mL, no transfusion 
required  Transfusion 
required  
RESPI[INVESTIGATOR_122779]  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) 
Cough  Transient - no 
treatment  Persistent  cough;  Interferes  with 
daily activities  
Bronchospasm,  Acute  transient; no 
treatment;  71% 
- 80% FEV1  of 
peak  flow requires treatment; 
normalizes with 
bronchodilator; FEV1 
60% - 70% (of peak  flow)  no normalization 
with 
bronchodilator; 
FEV1 <60% of  
peak  flow 
Dyspnea  Does not 
interfere  with 
usual and 
social 
activities  Interferes  with usual  and 
social activities, no 
treatment  Prevents daily and 
usual  social  activity 
or requires 
treatment  
GASTROINTESTINAL  Mild  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) 
Vomiting  No 
interference 
with activity  or 
1 - 2 
epi[INVESTIGATOR_1841]/24 
hours  Some interference with 
activity  or > 2 epi[INVESTIGATOR_1841]/24 
hours  Prevents daily 
activity  or requires 
IV hydration  
DMID  Protocol  18-0018  Version  4.0 
Phase  1 Trial  of Sm-p80 + GLA -SE Vaccine  04 January  2024  
DMID/NIAID/NIH  
CONFIDENTIAL  111  
  
Diarrhea  2 - 3 loose  or 
watery  stools 
or < 400 
gms/24  hours  4 - 5 loose  or watery  
stools  or 400 - 800 gms/24 
hours  6 or more loose or 
watery stools or > 
800gms/24  hours  or 
requires IV 
hydration  
SYSTEMIC 
REACTIONS  Mild  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) 
Allergic  Reaction  pruritus 
without  rash localized  urticaria  generalized 
urticaria; 
angioedema  or 
anaphylaxis  
All Other  conditions  Mild  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) 
Illness  or clinical  adverse 
event (as defined 
according to applicable 
regulations)  No 
interference 
with activity  Some  interference  with 
activity not requiring 
medical intervention  Prevents daily 
activity and 
requires  medical 
intervention  
 